

Objection Deadline: June 30, 2020 @ 12:00 p.m. (ET)

**UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> , ¹	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

**EIGHTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD APRIL 1, 2020 THROUGH APRIL 30, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant’s Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	April 1, 2020	April 30, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$1,198,111.20 (80% of \$1,497,639.00)	
Total expenses requested in this statement:	\$263.97	
Total fees and expenses requested in this statement:	\$1,198,375.17	
This is a(n): <u> X </u> Monthly Application ___ Interim Application ___ Final Application		

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD APRIL 1, 2020 THROUGH APRIL 30, 2020**

PROFESSIONAL	TITLE	RATE ⁽¹⁾	HOURS	FEES
Lisa Donahue	Managing Director	\$1,195	52.9	\$ 63,215.50
Richard Collura	Managing Director	\$1,090	99.8	108,782.00
Jesse DelConte	Director	\$950	187.0	177,650.00
Jay K Lynn	Director	\$950	2.5	2,375.00
Kevin M McCafferty	Director	\$950	145.8	138,510.00
Mark F Rule	Director	\$910	59.0	53,690.00
Michael Hartley	Director	\$840	55.8	46,872.00
Gabe J Koch	Director	\$840	163.9	137,676.00
Elizabeth S Kardos	Director	\$710	0.5	355.00
Ryan D Sublett	Senior Vice President	\$735	127.8	93,933.00
Isabel Arana de Uriate	Senior Vice President	\$690	136.9	94,461.00
Jon D Hecht	Senior Vice President	\$690	143.0	98,670.00
David Samikkannu	Senior Vice President	\$690	7.6	5,244.00
Sam J Canniff	Senior Vice President	\$645	147.0	94,815.00
Kristina Galbraith	Senior Vice President	\$645	11.8	7,611.00
Tracy L Jones	Senior Vice President	\$645	0.3	193.50
Kyoko Shibuya	Senior Vice President	\$645	8.6	5,547.00
Fernando O Silva	Senior Vice President	\$645	119.4	77,013.00
Hannah E Wells	Senior Vice President	\$645	0.6	387.00
Kaitlyn A Sundt	Senior Vice President	\$510	3.4	1,734.00
Andrew D DePalma	Vice President	\$515	194.6	100,219.00
Hart Ku	Vice President	\$515	6.3	3,244.50
Sam K Lemack	Vice President	\$515	179.3	92,339.50
Nate A Simon	Vice President	\$515	158.1	81,421.50
Tammy Brewer	Vice President	\$450	16.0	7,200.00
Kiera M Davids	Vice President	\$415	2.2	913.00
Andrea M LeBar	Associate	\$375	7.5	2,812.50
Paraskevas Moisakis	Associate	\$250	0.5	125.00
Roy Ellis Ochoa	Consultant	\$420	1.5	630.00
Total Professional Hours and Fees			2,039.6	\$ 1,497,639.00
Less 50% Travel Fees				-
Subtotal				\$ 1,497,639.00
Less 20% Holdback				(299,527.80)
Invoice Total				\$ 1,198,111.20

⁽¹⁾ Travel time rates are reduced by 50%

Average Billing Rate **\$ 734.28**

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD APRIL 1, 2020 THROUGH APRIL 30, 2020**

CODE	MATTER CATEGORY	HOURS	FEES
101	Chapter 11 Process/Case Management	112.5	\$ 95,824.00
103	Cash Management	209.9	114,976.00
104	Communication with Interested Parties	212.5	121,614.50
105	U.S. Trustee / Court Reporting Requirements	19.4	15,823.50
106	Business Analysis & Operations	867.8	688,911.00
108	Executory Contracts	2.3	1,924.00
109	Claims Process	0.8	760.00
110	Special Projects	15.7	10,691.50
113	Fee Statements and Fee Applications	29.7	13,989.50
114	Court Hearings	4.3	3,074.50
115	Forensic Analysis	564.7	430,050.50
		2,039.6	\$ 1,497,639.00
		Average Billing Rate	\$ 734.28

⁽¹⁾ *Travel time rates are reduced by 50%*

ALIXPARTNERS, LLP

SUMMARY OF EXPENSES
FOR THE PERIOD APRIL 1, 2020 THROUGH APRIL 30, 2020

EXPENSE CATEGORY	EXPENSE
Legal Fees	70.00
Other	193.97
Total	\$ 263.97

AlixPartners, LLP (“AlixPartners”), as Financial Advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Eighth Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period April 1, 2020 through April 30, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* (Docket No. 528) and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$1,497,639.00, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$263.97, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$1,198,111.20 (80% of \$1,497,639.00) and expenses in the amount of \$263.97, for a total amount of \$1,198,375.17.

Dated: June 16, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

Alix Partners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/01/20	SJC	Review and compilation of distributions for selected transactions.	3.00
04/01/20	SJC	Review and compilation of distributions for selected transactions (continued).	3.00
04/01/20	JD	Review ongoing work streams and plan go forward staffing.	0.50
04/01/20	JD	Review ongoing work stream progress and create agenda for update call with management, Davis Polk and PJT.	0.60
04/02/20	JD	Review documents being produced in response to various diligence questions from the UCC and AHC.	0.80
04/02/20	JD	Review materials provided in response to certain business development agreements.	0.50
04/02/20	JD	Review open questions from the department of labor and associated responses.	0.30
04/02/20	JD	Review diligence question list from Duff & Phelps and review data room for potential responses.	0.60
04/02/20	SJC	Review and compilation of distributions for selected transactions.	3.20
04/02/20	SJC	Review and compilation of distributions for selected transactions (continued).	3.00
04/03/20	SJC	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	SKL	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	IA	Attend weekly team status update call with I. Arana, S.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	
04/03/20	LJD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	MFR	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	MH	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	FOS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	JD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	DS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	GJK	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/03/20	JDH	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/03/20	ADD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, M. Hartley, J. Hecht, G. Koch, S. Lemack, M. Rule, D. Samikkannu, F. Silva, (all AlixPartners)	0.70
04/06/20	SJC	Compile distribution support for ex-us distributions.	3.00
04/08/20	DS	Review draft Customer Programs report.	0.30
04/09/20	JD	Meeting with G. Koch, M. Hartley, L. Donahue (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	0.40
04/09/20	MH	Meeting with G. Koch, J. DelConte, L. Donahue (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	0.40
04/10/20	FOS	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	MFR	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	MH	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Simon, R. Sublett, (all AlixPartners)	
04/10/20	LJD	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	LJD	Call with J. DelConte, L. Donahue (both AlixPartners) re: follow up questions from the Board on the business plan presentation.	0.20
04/10/20	SJC	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	SKL	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	IA	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	JD	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners) re: follow up questions from the Board on the business plan presentation.	0.20
04/10/20	JD	Call with J. Turner (PJT) re: Rhodes planning.	0.30
04/10/20	RC	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Simon, R. Sublett, (all AlixPartners)	
04/10/20	NAS	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	RDS	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	KM	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	ADD	Attend weekly team status update call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, M. Hartley, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/10/20	ADD	Prepare for AlixPartners Purdue engagement team update call.	0.60
04/12/20	JD	Call with C. Robertson (Davis Polk) re: HRT motion. Research federal and state spending on Naloxone.	0.50
04/13/20	MH	Scheduled transitions of case management responsibilities to new consultants.	0.50
04/13/20	KM	Coordination of Rhodes business plan implementation effort.	0.20
04/14/20	JD	Correspondence with C. Robertson (Davis Polk) and E. Kardos (AlixPartners) re: fee examiner and interim fee applications.	0.50
04/14/20	JD	Review materials provided for RxPricing data examples.	0.70
04/14/20	JD	Review correspondence and materials proposed to be	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		produced for various UCC diligence requests.	
04/15/20	JD	Review updated contract signing authority listing.	0.30
04/15/20	JD	Review latest third party consent forms and latest presentations given those permissions.	0.40
04/15/20	JD	Review 363 primer materials from Davis Polk to share with Purdue.	0.50
04/16/20	JD	Call with R. Aleali (Purdue) re: updated case progress and outstanding work streams.	0.50
04/16/20	JD	Call with E. Vonnegut, T. Graulich (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte (both AlixPartners) re: case update and team coordination.	1.10
04/16/20	JD	Review UCC diligence request and progress to date on providing certain items. Look through Intralinks to see what has been uploaded.	1.00
04/16/20	ADD	Research specific entity included in conflict list at request of Davis Polk.	0.60
04/17/20	ADD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	RDS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	KM	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/17/20	JD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	JD	Correspondence with C. Oluwole (Davis Polk) and A. DePalma (AlixPartners) re: diligence materials and VDR costs. Review Intralinks quotes and contract.	0.80
04/17/20	DS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	NAS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	JDH	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	MFR	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	LJD	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	FOS	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/17/20	IA	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	SKL	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/17/20	SJC	Attend weekly team status update call with I. Arana, S. Canniff, J. DelConte, A. DePalma, L. Donahue, J. Hecht, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.80
04/19/20	LJD	Review correspondence re: creditor presentation	0.30
04/19/20	LJD	Review and comment on monthly reporting package.	1.50
04/19/20	LJD	Review the creditor presentation.	1.60
04/19/20	LJD	Work on staffing issues.	0.30
04/19/20	JD	Correspondence with A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: next steps in providing certain materials to the creditor groups.	0.40
04/20/20	JD	Correspondence with E. Diggs (Davis Polk) and H. Ku (AlixPartners) re: contract database comparison. Review Intralinks for uploaded contracts.	1.00
04/20/20	JD	Correspondence with E. Kardos (AlixPartners) re: fee examiner.	0.30
04/20/20	JD	Review correspondence re: permission to disclose Nielsen data.	0.40
04/20/20	JD	Correspondence with E. Kardos (AlixPartners) and C. Robertson (Davis Polk) re: hearing on Wednesday.	0.20
04/20/20	LJD	Review and comment on revised creditor presentation.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/20/20	LJD	Update call with PJT.	0.40
04/20/20	LJD	Call with K. Buckfire (Board member)	0.70
04/20/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.40
04/21/20	LJD	Review correspondence.	0.30
04/21/20	JD	Review creditor diligence emails to provide to Davis Polk in preparation for court hearing.	1.00
04/21/20	JD	Review historical billings and create summary of forensic billings.	0.60
04/21/20	JD	Review correspondence from A. DePalma (AlixPartners) re: redaction search terms.	0.30
04/21/20	JD	Call with J. DelConte, R. Collura (both AlixPartners) re: hearing preparation questions.	0.20
04/21/20	RC	Call with J. DelConte, R. Collura (both AlixPartners) re: hearing preparation questions.	0.20
04/22/20	JD	Call with J. Turner (PJT) re: post D&P catch up call.	0.20
04/22/20	JD	Review draft board minutes to posted for creditor advisors.	1.00
04/22/20	JD	Correspondence with J. Turner (PJT) re: buyers log.	0.30
04/22/20	JD	Review and edited latest creditor presentation.	0.70
04/22/20	JD	Review updated Project Catalyst slide.	0.40
04/22/20	JD	Review summary of contract listings from Intralinks and from DPW site.	0.70
04/23/20	JD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case progress and go forward planning.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/23/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence.	0.30
04/23/20	JD	Meeting with M. Huebner (Davis Polk), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Kesselman (Purdue), S. Birnbaum (Dechert) and the mediators re: question and answer session.	2.40
04/23/20	JD	Review interim fee application order and check AlixPartners figures against fee applications.	0.30
04/23/20	JD	Correspondence with K. Laurel (Purdue) re: employee stats.	0.40
04/23/20	LJD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case progress and go forward planning.	1.10
04/23/20	LJD	Review and comment on creditor deck.	1.50
04/23/20	KM	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case progress and go forward planning.	0.70
04/23/20	RDS	Create scenario analysis slide reviewing a fill-the-plant scenario.	1.30
04/23/20	RDS	Call with R. Schnitzler, J. Turner (both PJT), P. Strassburger, D. Lundie, J. Lowne, (all Purdue), K. McCafferty (AlixPartners) re: Project Catalyst	0.50
04/23/20	RDS	Comment on external lender informational document.	1.00
04/23/20	RDS	Preparation for discussion on Project Catalyst.	0.40
04/23/20	RDS	Call with D. Lundie, D. Fogel (both Purdue), K. McCafferty (AlixPartners) re: Project Catalyst analysis.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/24/20	RDS	Analysis of Customer and Product Profitability -DAG.	1.70
04/24/20	RDS	Analysis of IQVIA data to draw insight for API partnership revenue growth assumptions.	1.20
04/24/20	RDS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	ADD	Review current status of diligence work stream in preparation for AlixPartners engagement team update call.	0.50
04/24/20	ADD	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	KM	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	DS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	LJD	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/24/20	LJD	Weekly update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.20
04/24/20	LJD	Update call with K. Buckfire (Board member).	0.20
04/24/20	MFR	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	FOS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	SKL	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	SJC	Review support for 2015 distributions (continued).	2.00
04/24/20	SJC	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	IA	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	NAS	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	
04/24/20	NAS	Prepare for AlixPartners Purdue engagement team weekly update call.	0.50
04/24/20	JD	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	JD	Correspondence with D. Consola (Davis Polk) re: fee examiner.	0.20
04/24/20	RC	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	JDH	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/24/20	GJK	Attend weekly team status update call with L. Donahue, I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, D. Samikkannu, F. Silva, N. Simon, R. Sublett, (all AlixPartners)	0.70
04/27/20	LJD	Review board deck for meeting on 4/30.	1.50
04/29/20	LJD	Call with J. Dubel (Purdue) re: expectations for April 30 board meeting.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
04/29/20	LJD	Review and respond to email correspondence.	0.40
04/29/20	LJD	Review updated info for board meeting.	1.50
04/29/20	JD	Correspondence with J. Lowne (Purdue), T. Melvin (PJT) and A. DePalma (AlixPartners) re: diligence responses.	0.60
04/29/20	JD	Call with R. Aleali (Purdue) re: proposed diligence responses.	0.30
04/29/20	JD	Follow up call with R. Aleali (Purdue) re: open diligence items.	0.20
04/29/20	JD	Review Rhodes transformation proposal and correspondence with J. Lowne (Purdue) re: same.	0.50
04/30/20	LJD	Prepare for and attend Purdue board meeting.	4.20
04/30/20	IA	Review March ordinary course professionals payments report to be filed.	0.80
Total			<u>112.50</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	4.70	515.00	2,420.50
Sam K Lemack	3.00	515.00	1,545.00
Nate A Simon	2.80	515.00	1,442.00
Fernando O Silva	3.00	645.00	1,935.00
Sam J Canniff	20.20	645.00	13,029.00
David Samikkannu	2.50	690.00	1,725.00
Jon D Hecht	2.20	690.00	1,518.00
Isabel Arana de Uriarte	3.80	690.00	2,622.00
Ryan D Sublett	9.50	735.00	6,982.50
Michael Hartley	2.40	840.00	2,016.00
Gabe J Koch	1.40	840.00	1,176.00
Mark F Rule	3.00	910.00	2,730.00
Kevin M McCafferty	3.20	950.00	3,040.00
Jesse DelConte	28.10	950.00	26,695.00
Richard Collura	1.70	1,090.00	1,853.00
Lisa Donahue	21.00	1,195.00	25,095.00
Total Hours & Fees	112.50		95,824.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/01/20	IA	Update operating expenses and AP actuals in Purdue 13 week cash flow model.	1.80
04/01/20	SKL	Continue to update the Customer Rebate section of the latest 13-week Rhodes cash forecast.	1.60
04/01/20	SKL	Finalize updates to the latest 13-week Rhodes cash forecast and circulate internally for review and sign-off.	2.30
04/01/20	SKL	Review the February financial deck and began preparing the February Flash report accordingly.	2.10
04/01/20	SKL	Finalize updates to and formatting of the February Flash report and circulated internally for review and sign-off.	2.40
04/02/20	SKL	Continue to review the Purdue rebates from the February cash actuals and implemented into the February Customer Programs report.	2.10
04/02/20	SKL	Continue to review the Rhodes rebates from the February cash actuals and implemented into the February Customer Programs report.	1.90
04/02/20	IA	Review updated company April rebate forecast and adjusted Purdue 13 week cash flow model to reflect latest assumptions and known near term payments.	1.70
04/02/20	IA	Review retained professionals and restructuring firm professional fee trackers included in latest Purdue 13 week forecast.	1.70
04/02/20	IA	Update variance reporting for Purdue forecast to actuals comparison for the week ended 03.27.	0.60
04/02/20	SKL	Reconcile the latest Purdue rebate information provided by E. Nowakowski (Purdue) and finalized updates to the Wholesaler Chargeback section of the February Customer Program's report.	1.30
04/02/20	SKL	Reconcile the latest Purdue rebate information provided by E. Nowakowski (Purdue) and finalized updates to the	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		Prompt Pay Discounts and Sales Returns pieces of the February Customer Program's report.	
04/02/20	SKL	Reconcile the latest Rhodes rebate information provided by P. Phouthasone (Rhodes Pharma) and finalized updates to the Prompt Pay Discounts and Sales Returns pieces of the February Customer Program's report.	1.50
04/02/20	DS	Update Rhodes cash flow model for FY 2020 budget details including cost allocations per product.	1.10
04/03/20	DS	Review particular wording of a section of weekly cash report.	0.10
04/03/20	JD	Review and provide comments on weekly cash forecast to actual analysis.	0.50
04/03/20	SKL	Reconcile the latest Rhodes rebate information provided by P. Phouthasone (Rhodes Pharma) and finalized updates to the Wholesaler Chargeback section of the February Customer Program's report.	1.10
04/03/20	SKL	Review the January Flash report and prepared and circulated updated deck per DPW and R. Aleali (Purdue) request.	1.20
04/03/20	SKL	Preparation of and finalize updates to the February Flash report and circulate to the AlixPartners team for final sign-off.	1.80
04/03/20	SKL	Finalize updates to the weekly cash reporting deck based off the latest feedback provided by E. Nowakowski (Purdue) and J. Liceaga (TXP).	2.20
04/03/20	SKL	Preparation of updated weekly cash reporting deck and circulated to the AlixPartners team for final sign-off.	2.10
04/03/20	IA	Review cash actuals report for week ended 03/27.	1.30
04/06/20	SKL	Continue updating the Retained Professional tracker and forecast with the latest Interim Fee application	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		information and updated the Purdue and Rhodes cash forecast accordingly.	
04/06/20	SKL	Update the Restructuring Professional tracker and forecast with the latest Interim Fee application information and updated the Purdue and Rhodes cash forecast accordingly.	2.10
04/06/20	SKL	Update the Medicaid section of the February Customer Programs report with the state-by-state Medicaid breakout for Rhodes.	1.10
04/06/20	SKL	Update the Medicaid section of the February Customer Programs report with the state-by-state Medicaid breakout for Purdue.	1.00
04/06/20	SKL	Preparation of and finalized the GPO fee section of the February Customer Programs report.	1.30
04/06/20	SKL	Finalize updates to the Private Insurance Program rebates section of the February Customer Programs report and circulated to C. Ostrowski (Purdue) for final sign-off.	1.20
04/06/20	IA	Review updated professional fees schedule now showing 20% holdback fee payments.	1.40
04/06/20	IA	Review updated short term weekly collections forecast prepared by TXP.	0.40
04/06/20	JD	Review and provide comments on the latest cash flow forecast. Compare against previous forecast and latest actual results.	1.20
04/06/20	DS	Review updates to the cash forecast made by S. Lemack (AlixPartners).	0.20
04/07/20	SKL	Continue finalizing reconciliation of the Rhodes' rebates and updated the Rhodes rebate summary of the February Customer Programs report accordingly.	2.30
04/07/20	SKL	Finalize reconciliation of the Purdue rebates and updated	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		the Purdue rebate summary of the February Customer Programs report accordingly.	
04/07/20	SKL	Preparation and finalization of the Medicare Part D rebate section of the February Customer Programs report based on the latest feedback provided by C. Ostrowski (Purdue) and re-circulated for final sign-off.	2.90
04/08/20	SKL	Review and reconcile the latest Rhodes weekly sales report and circulated the updated version for final sign-off.	1.30
04/08/20	SKL	Review and reconcile the latest Purdue weekly sales report and circulated the updated version for final sign-off.	1.40
04/08/20	SKL	Review the latest East West cash transactions provided by J. Liceaga (TXP) and began categorizing accordingly for the weekly cash report.	2.30
04/08/20	SKL	Review the latest Paysource cash transactions and began categorizing accordingly for the weekly cash report.	1.80
04/08/20	SKL	Review and reconcile the latest IAC activity re: weekly cash report and updated the week ending 04/03 report accordingly.	1.60
04/09/20	SKL	Review the latest feedback provided by J. Liceaga (TXP) and E. Nowakowski (Purdue) and updated the weekly cash report accordingly.	2.10
04/09/20	SKL	Preparation and finalization of redacted version of the February Customer Programs report and circulated to the Davis Polk team accordingly.	1.70
04/09/20	SKL	Update the latest cash forecast based on the feedback provided by the company and re-circulated for final sign-off.	0.80
04/09/20	SKL	Finalize updates to the latest cash forecast and circulated	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		to the company accordingly for final sign-off.	
04/09/20	SKL	Finalize updates to the Purdue summary re: weekly cash report.	1.20
04/09/20	SKL	Finalize updates to the Rhodes summary re: weekly cash report.	1.00
04/10/20	SKL	Preparation of the latest Purdue forecast-to-actuals variance report re: weekly cash report.	1.40
04/10/20	SKL	Preparation of the latest Rhodes forecast-to-actuals variance report re: weekly cash report.	1.10
04/10/20	SKL	Review the latest Tech Ops scorecard and updated the February flash report accordingly.	1.00
04/10/20	SKL	Continue to finalize the February flash report and circulated internally for final sign-off.	2.30
04/10/20	SKL	Finalize updates to the IAC section of the latest weekly cash report and re-circulated internally for final sign-off.	1.20
04/10/20	SKL	Finalize updates to the latest weekly cash reporting deck and circulated internally for review and sign-off.	1.20
04/13/20	SKL	Finalize updates to the weekly cash report and circulate to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.10
04/13/20	SKL	Reviewed and reconciled the Purdue and Rhodes March bank statements and began preparing the account balance section of the March Monthly Operating Report.	2.30
04/13/20	SKL	Finalize updates to the account balance section of the March Monthly Operating report and provided to the TXP team for final sign-off.	2.10
04/13/20	SKL	Finalize updates to the February Flash report and circulated to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/13/20	SKL	Review the latest financial reporting inquiry from the Province team and provided updates accordingly.	0.70
04/13/20	SKL	Made final updates to the forecast-to-variance slides of the weekly cash report and updated the deck accordingly.	0.90
04/13/20	IA	Review cash actuals report for week ended 04/01.	1.40
04/13/20	IA	Follow up with payroll (TXP) on payments for employee benefit programs and reconciled to cash actuals report.	0.70
04/13/20	IA	Draft outline of LTRP payment bridges for discussion with HR.	0.90
04/13/20	IA	Update creditor draft slides to incorporate redactions and comments received from legal.	1.80
04/13/20	JD	Review and provide comments on weekly cash forecast to actual report.	0.50
04/14/20	DS	Meeting with S. Lemack (AlixPartners) re: the Rhodes cash forecast and implementation plan for the Rhodes 2020 budget.	0.80
04/14/20	SKL	Finalized updates to the latest cash report and flash report and circulated to the Davis Polk team to begin the production process.	0.60
04/14/20	SKL	Review and reconcile the March cash activity and prepare the latest cash activity report for the March Monthly Operating Report.	2.10
04/14/20	SKL	Finalized updates to the March cash activity reconciliation and circulated the latest cash activity report internally to include in the March Monthly Operating Report.	2.40
04/14/20	SKL	Meeting with D. Samikkannu (AlixPartners) re: the Rhodes cash forecast and implementation plan for the Rhodes 2020 budget.	0.80
04/14/20	SKL	Review and reconciliation of the latest East West	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		transaction report and began categorizing accordingly re: weekly cash reporting.	
04/14/20	SKL	Review and reconciled the latest cash investment activity and updated the Purdue and Rhodes summaries accordingly re: weekly cash reporting.	1.30
04/15/20	SKL	Review and reconciled the latest Paysource transaction report and began categorizing accordingly re: weekly cash reporting.	2.50
04/15/20	SKL	Review and reconciled the latest IAC cash activity, prepared list of open items for J. Liceaga (TXP) and E. Nowakowski (Purdue), and updated the IAC sections accordingly re: weekly cash reporting.	1.60
04/15/20	SKL	Update the weekly cash reporting summaries based on the latest feedback provided by J. Liceaga (TXP) and E. Nowakowski (Purdue).	1.70
04/15/20	SKL	Preparation of the latest Rhodes weekly sales report based on the information provided by P. Phouthasone (Purdue).	0.80
04/16/20	SKL	Review the 2020 Rhodes budget prior to implementing into the Rhodes cash forecast.	1.10
04/16/20	SKL	Finalize updates to the Purdue/Rhodes bank balances and updated the March Monthly Operating Report accordingly,.	1.30
04/16/20	SKL	Preparation of updates to the Purdue forecast and updated the Purdue forecast-to-actuals accordingly.	1.60
04/16/20	SKL	Preparation of updates to the Rhodes forecast and updated the Rhodes forecast-to-actuals accordingly.	1.40
04/16/20	SKL	Finalize updates to the Purdue and Rhodes IAC summaries based on the latest feedback provided by E. Nowakowski (Purdue).	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/16/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: accounts payable and critical vendor process.	0.60
04/17/20	IA	Provide comments to cash report for week ended 04/10.	0.20
04/17/20	IA	Review cash report for week ended 04/10.	1.40
04/17/20	SKL	Continue to update the latest weekly cash report and prepare and circulate the reporting deck for review and sign-off.	2.00
04/17/20	SKL	Preparation of the latest Purdue weekly sales report and circulated to the AlixPartners team accordingly.	0.70
04/17/20	SKL	Finalize updates to the latest cash report and re-circulated for final approval.	2.30
04/17/20	SKL	Implement the 2020 Rhodes budget into the latest forecast.	2.30
04/17/20	DS	Review cash report and provide comments to S. Lemack (AlixPartners).	0.10
04/20/20	JD	Review and provide comments on latest cash flow forecast to actual report. Correspondence with S. Lemack (AlixPartners) re: same.	0.80
04/20/20	SKL	Finalize updates to the weekly cash report and circulated to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.20
04/20/20	SKL	Preparation of vendor payment analysis per M. Hartley request.	0.60
04/20/20	SKL	Preparation of updated forecast-to-actual variance analysis and circulated updated deck for final sign-off.	1.60
04/20/20	SKL	Review and reconcile the latest EastWest cash transaction report and began categorizing accordingly.	2.30
04/20/20	SKL	Review and reconcile the Paysource transactions report and began categorizing accordingly.	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/21/20	SKL	Call with D. Samikkannu (AlixPartners) re: Rhodes budget update.	0.70
04/21/20	SKL	Review and reconciled the latest IAC cash activity, prepared list of open items for J. Liceaga (TXP) and E. Nowakowski (Purdue), and updated the IAC sections accordingly re: weekly cash reporting.	2.60
04/21/20	SKL	Finalize updates to the Rhodes and Purdue weekly sales report and circulated to the Davis Polk team to begin the production process.	1.00
04/21/20	SKL	Continue to update the Rhodes cash forecast with the latest COGS info from the 2020 budget.	1.30
04/21/20	DS	Call with S. Lemack (AlixPartners) re: Rhodes budget update.	0.70
04/22/20	DS	Review of cash report.	0.40
04/22/20	SKL	Update the weekly cash reporting summaries based on the latest feedback provided by J. Liceaga (TXP).	2.10
04/22/20	SKL	Update the Rhodes cash forecast with the latest Rhodes Pharma product sales info.	2.60
04/22/20	SKL	Update the Rhodes cash forecast with the latest royalty estimates from the 2020 budget.	2.10
04/22/20	SKL	Update the operating expense section of the Rhodes forecast with the latest operating expense breakout from the 2020 Rhodes budget.	1.40
04/23/20	SKL	Review of the Purdue 2020 budget and support files to begin updating the forecast accordingly before today's budget call with E. Nowakowski (Purdue).	2.30
04/23/20	SKL	Update the Purdue forecast with the latest cash actuals and prepared the latest forecast-to-variance report.	1.80
04/23/20	SKL	Update the Rhodes forecast with the latest cash actuals	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		and prepared the latest forecast-to-variance report.	
04/23/20	SKL	Continue to review the operating expense breakout of the Rhodes 2020 budget and updated the Rhodes forecast accordingly.	1.10
04/23/20	SKL	Meeting with E. Nowakowski (Purdue) and I. Arana, S. Lemack (both AlixPartners) to review the 2020 Purdue P&L and Balance Sheet.	1.00
04/23/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) re: the 2020 Purdue P&L and 13-week Cash Forecast.	0.80
04/23/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) re: the 2020 Purdue P&L and 13-week Cash Forecast.	0.80
04/23/20	IA	Review 2019 Purdue budget backup files and put together request list for discussion with Purdue finance prior to updating cash forecast to match latest 2020 budget.	1.70
04/23/20	IA	Review latest fee applications filed on docket to update cash forecast.	0.80
04/24/20	IA	Review and provide comments to cash actuals report for week ended 04/17.	1.40
04/24/20	IA	Review weekly rebate payments for March and April for actuals report and upcoming updated Purdue forecast.	1.20
04/24/20	SKL	Finalize updates to the weekly cash report based on the feedback provided by E. Nowakowski (Purdue).	2.40
04/24/20	SKL	Finalize updates to the weekly cash report and prepared the weekly cash report deck and circulated internally for final sign-off.	2.20
04/24/20	SKL	Review the latest cash inquiries provided by Province and prepared list of updates accordingly.	0.60
04/24/20	SKL	Began updating the Rhodes cash forecast with the latest Rhodes Tech information provided in the 2020 Rhodes	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		budget.	
04/24/20	DS	Review of cash report.	0.10
04/24/20	JD	Review and provide comments on weekly cash forecast to actuals.	0.50
04/27/20	DS	Call with S. Lemack (AlixPartners) re: cost buildup of Rhodes budget.	0.90
04/27/20	SKL	Meeting with I. Arana and S. Lemack (both AlixPartners) re: the 2020 Purdue budget and 13-week Cash Forecast.	0.30
04/27/20	SKL	Meeting with D. Samikkannu (AlixPartners) and S. Lemack (AlixPartners) re: the 2020 Rhodes budget and 13-week Cash Forecast.	0.90
04/27/20	SKL	Review latest deliverables provided by E. Nowakowski (Purdue) and prepared updated breakdown of outstanding requests.	1.40
04/27/20	SKL	Prepare and circulate latest cash reporting package for the Davis Polk team to move into production.	0.50
04/27/20	SKL	Review the February flash report and updated the deck for non-PEO designation.	2.10
04/27/20	SKL	Continue to review and finalize updates to the Rhodes cash forecast re: 2020 budget implementation.	2.20
04/27/20	SKL	Continue updates to the Rhodes cash forecast based on feedback provided	1.20
04/27/20	IA	Follow up with company on request from UCC for additional details on projected restricted cash.	0.90
04/27/20	IA	Draft response to UCC request for additional information on restricted cash in business plan projections.	1.50
04/27/20	IA	Review retention trackers and 2020 estimated payments to inform PHI cash flow analysis.	1.40
04/27/20	IA	Meeting with I. Arana and S. Lemack (both AlixPartners)	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		re: the 2020 Purdue budget and 13-week Cash Forecast.	
04/28/20	SKL	Continue to finalize the Rhodes Tech sales assumptions piece of the Rhodes cash forecast.	2.10
04/28/20	SKL	Continue to review and make updates to the Rhodes Tech COGS and Operating Expense section of the Rhodes cash forecast.	2.50
04/28/20	SKL	Review and reconciled the latest EastWest cash transaction report and began categorizing accordingly.	2.40
04/28/20	SKL	Review the latest IAC cash activity from this past week's cash transactions and began creating the IAC summaries accordingly.	1.30
04/29/20	SKL	Review and reconciled the Paysource transactions report and began categorizing accordingly.	2.00
04/29/20	SKL	Review the latest investment activity provided in last week's cash transaction report and updated the Purdue and Rhodes summaries accordingly.	0.70
04/29/20	SKL	Continue to finalize implementation of the 2020 Rhodes Pharmaceutical and Rhodes Tech budgets into the Rhodes cash forecast.	2.00
04/29/20	SKL	Update the cash transaction categorizations based on the latest feedback provided by J. Liceaga (TXP).	1.60
04/29/20	SKL	Continue to finalize the weekly cash report and prepared and circulated list of open cash inquiries to E. Nowakowski (Purdue).	1.60
04/29/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) to continue discussing the Purdue cash forecast and implementation plan for the Purdue 2020 budget.	0.50
04/29/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) to continue discussing the Purdue cash forecast and implementation plan for the Purdue 2020 budget.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
04/30/20	SKL	Create accounts payable release file.	0.80
04/30/20	SKL	Review the February flash report and March financials report and prepared list of items re: FTI inquiries.	1.50
04/30/20	SKL	Begin updating the Purdue sales forecast of the Purdue cash forecast based on the latest feedback provided from E. Nowakowski (Purdue).	2.20
04/30/20	SKL	Walkthrough accounts payable release process with M. Hartley (AlixPartners) and S. Lemack (AlixPartners).	0.70
04/30/20	SKL	Call with D. Samikkannu (AlixPartners) to review overall Rhodes budget update.	0.40
04/30/20	SKL	Continue updating the Purdue cash forecast with the latest 2020 budget information.	1.40
04/30/20	SKL	Review and reconcile the latest Rhodes weekly sales by product information.	0.60
04/30/20	DS	Call with S. Lemack (AlixPartners) to review overall Rhodes budget update.	0.40
Total			209.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	175.80	515.00	90,537.00
David Samikkannu	4.80	690.00	3,312.00
Isabel Arana de Uriarte	25.80	690.00	17,802.00
Jesse DelConte	3.50	950.00	3,325.00
Total Hours & Fees	209.90		114,976.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/01/20	JD	Correspondence with M. Huebner and E. Vonnegut (both Davis Polk) re: HRT.	0.40
04/01/20	NAS	Follow-up with Counsel (DPW) re: 2YR lookback on insider payments as requested by UCC.	0.20
04/01/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	3.00
04/01/20	ADD	Review and redact confidential information from 2018 board materials.	3.20
04/01/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	2.60
04/02/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	3.10
04/02/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	2.00
04/02/20	ADD	Review and redact confidential information from 2018 board materials.	3.20
04/02/20	ADD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: third party confidentiality.	0.30
04/02/20	ADD	Call with J. DelConte, A. DePalma (both AlixPartners) re: open diligence items.	0.20
04/02/20	JD	Call with J. DelConte, A. DePalma (both AlixPartners) re: open diligence items.	0.20
04/02/20	JD	Call with A. DePalma, J. DelConte (both AlixPartners) and C. Oluwole (Davis Polk) re: third party confidentiality.	0.30
04/02/20	JD	Call with R. Aleali, J. Lowne, J. Doyle (Purdue) and J. Turner (PJT) re: Rhodes business plan.	0.30
04/02/20	JD	Call with R. Aleali (Purdue) re: open business plan points.	0.30
04/03/20	ADD	Call with Davis Polk diligence team re: outstanding	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		diligence requests.	
04/03/20	ADD	Review and redact confidential information from 2018 board materials.	2.80
04/03/20	ADD	Call with Davis Polk M&A and Diligence teams re: Rhodes Board Materials.	0.60
04/06/20	ADD	Update diligence tracker.	2.10
04/06/20	ADD	Review and redact confidential information from board minutes.	3.20
04/06/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	1.70
04/06/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.50
04/06/20	JD	Review recent statements of work for Pinney and Associates.	0.50
04/06/20	JD	Review and comment on draft talking points for HRT call.	0.40
04/06/20	FOS	Review Avrio Health LP board minutes and resolutions and redact confidential information for production to Committees.	3.50
04/07/20	FOS	Review board minutes and resolutions and redact confidential information for production to Committees.	1.60
04/07/20	ADD	Review and redact confidential information from board minutes.	3.10
04/07/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	1.90
04/07/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.40
04/08/20	ADD	Analysis of intercompany agreements compiled in preparations for diligence request response.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/08/20	ADD	Upload production provided by Davis Polk to that data room.	1.30
04/08/20	ADD	Review and redact confidential information from board minutes.	2.90
04/09/20	ADD	Review and prepare documentation submitted in response to diligence request in preparation for production.	2.70
04/09/20	ADD	Review outstanding diligence requests and follow up with to obtain responsive files.	2.50
04/09/20	ADD	Review and redact confidential information from board minutes.	2.80
04/09/20	IA	Review February flash report before distribution to management for approval.	0.70
04/09/20	JD	Review diligence responses re: S. Baker's historical job titles.	0.50
04/09/20	JD	Review historical board minutes prior to having them provided to creditor advisors.	2.10
04/10/20	JD	Call with J. Lowne, P. Strassburger (both Purdue), E. Vonnegut, C. Robertson (both Davis Polk), J. Turner (PJT) and all UCC and AHC creditor advisors re: HRT motion.	1.00
04/10/20	JD	Call with K. Knechtel and B. Bromberg (both FTI) re: business planning progress.	0.40
04/10/20	ADD	Upload production provided by Davis Polk to the data room.	2.60
04/13/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.20
04/13/20	ADD	Review and redact third party information from board minutes and resolutions.	3.10
04/13/20	ADD	Research and review license agreements and royalty payments.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/13/20	ADD	Review and follow up with outstanding diligence requests.	0.90
04/13/20	JD	Call with J. Turner and T. Melvin (PJT) creditor diligence follow ups.	0.30
04/13/20	JD	Review Duff & Phelps diligence questions in advance of call this afternoon. Review materials identified as responsive to various diligence questions.	1.50
04/13/20	IA	Review requests received from UCC and draft responses on status of open items.	1.30
04/14/20	JD	Review diligence request list from Province. Review against list sent across last week. Review status of materials provided to date.	1.50
04/14/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.60
04/14/20	ADD	Review and redact third party information from board minutes and resolutions.	2.40
04/14/20	ADD	Review status of outstanding diligence request in preparation for call with Davis Polk.	1.70
04/14/20	ADD	Call with Davis Polk diligence team to review status of outstanding diligence request in preparation for call with UCC advisors.	2.80
04/15/20	ADD	Call with Davis Polk Diligence team and Purdue re: outstanding diligence request.	0.50
04/15/20	ADD	Call with Davis Polk Diligence team and Purdue outside Counsel re: redaction process.	0.30
04/15/20	ADD	Review of IP and transfer pricing material for responsiveness to diligence requests.	1.40
04/15/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.30
04/15/20	ADD	Review and redact third party information from board	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		minutes and resolutions.	
04/16/20	ADD	Review documentation submitted in response to diligence request at request of Davis Polk.	0.80
04/16/20	ADD	Review diligence request and update tracker.	1.80
04/16/20	ADD	Review and follow up with outstanding diligence request.	1.70
04/16/20	ADD	Review board materials submitted and prepared in response to diligence requests.	2.40
04/16/20	IA	Follow up on diligence requests related to insider titles and job history.	0.70
04/16/20	IA	Follow up with D. Warren (Purdue) to reconcile differences between latest LTRP tracker and amounts submitted to finance team for accruals.	0.50
04/16/20	IA	Review market overview and product forecast documents to identify third party data that requires third party consent prior to disclosure.	0.60
04/17/20	IA	Draft initial responses to diligence questions received from UCC (Province) to be reviewed with PJT.	1.00
04/17/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.80
04/17/20	ADD	Review and redact third party information from board minutes and resolutions.	2.70
04/17/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	1.80
04/19/20	ADD	Upload documents processed by Davis Polk in response to diligence requests to the data room for the Committees.	2.30
04/20/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.30
04/20/20	ADD	Review outstanding diligence and update diligence tracker.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/20/20	ADD	Review and redact third party information from board minutes and resolutions.	3.10
04/20/20	ADD	Review files uploaded with the current weeks production and check user access.	1.20
04/20/20	IA	Update proposed answers to UCC diligence questions received from Province.	1.20
04/20/20	JD	Review and provide comments re: draft responses to various UCC diligence requests.	0.60
04/21/20	JD	Review latest Rhodes and Purdue IMS data prior to it being uploaded for the creditor advisors.	0.70
04/21/20	JD	Review latest diligence tracker from PJT and provide comments re: same.	0.70
04/21/20	ADD	Compile diligence request statistics at request of Davis Polk.	3.20
04/21/20	ADD	Follow up with outstanding diligence items.	1.40
04/21/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.70
04/21/20	ADD	Review and redact third party information from board minutes and resolutions.	1.80
04/21/20	ADD	Call with Davis Polk diligence team and Davis Polk eDiscovery team to review updated direct diligence production process.	0.70
04/22/20	ADD	Upload files processed and designated by Davis Polk to the data room.	2.10
04/22/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.50
04/22/20	ADD	Review and redact third party information from board minutes and resolutions.	2.90
04/22/20	ADD	Draft correspondence request approval to upload files to	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		the data room.	
04/22/20	JD	Call with J. Feltman, B. Bartell (both Duff & Phelps) and T. Coleman and J. Turner (both PJT) re: case update.	0.70
04/23/20	ADD	Review new diligence request and draft correspondence to request responsive materials.	1.50
04/23/20	ADD	Review and redact third party information from board minutes and resolutions.	2.90
04/23/20	ADD	Draft correspondence to request approval to upload files to the data room.	1.20
04/23/20	ADD	Review and compile materials submitted in response to diligence requests for processing.	2.50
04/24/20	ADD	Upload files processed and designated by Davis Polk to the data room.	3.10
04/24/20	ADD	Preparation of excel file for upload to data room.	1.70
04/24/20	ADD	Draft correspondence to request approval to upload files to the data room.	1.00
04/24/20	ADD	Review and redact third party information from board minutes and resolutions.	2.20
04/24/20	ADD	Call with Davis Polk diligence team re: diligence production for the upcoming weekend.	0.30
04/24/20	IA	Review diligence and status requests received from Province and provided answers.	1.60
04/25/20	ADD	Upload documents submitted in response to diligence requests and processed by Davis Polk to the data room.	1.80
04/27/20	ADD	Compile and review business development agreements submitted in response to diligence requests for processing.	1.60
04/27/20	ADD	Review and follow up with outstanding diligence requests.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/27/20	ADD	Review board minutes from 2008 to 2017 to document family member election and resignation dates.	2.90
04/27/20	ADD	Review board minutes from 2000 to 2007 to document family member election and resignation dates.	2.50
04/27/20	ADD	Call with Davis Polk diligence team re: outstanding diligence items.	0.40
04/27/20	JD	Call with M. Atkinson (Province) re: COVID donations.	0.20
04/27/20	JD	Correspondence with M. Atkinson (Province) and M. Diaz (FTI) re: COVID donations.	0.70
04/27/20	JD	Review comprehensive diligence question list received from FTI and check on answers and materials collected to date.	1.00
04/27/20	JD	Call with M. Diaz (FTI) re: COVID donations.	0.20
04/27/20	JD	Call with M. Diaz and B. Bromberg (both FTI) re: open diligence questions.	0.20
04/28/20	JD	Review existing responses to open UCC diligence items. Create comprehensive response document for purposes of posting to the data room.	3.30
04/28/20	JD	Review materials relating to OSU addiction center donations and ongoing work.	0.90
04/28/20	JD	Review correspondence between M. Atkinson (Province) and R. Collura (AlixPartners) re: open diligence items.	0.30
04/28/20	JD	Call with M. Huebner (Davis Polk), M. Kesselman, R. Silbert (both Purdue), S. Birnbaum, H. Coleman (both Dechert), J. Turner (PJT), J. DelConte, I. Arana (both AlixPartners) and the Hospital Group re: hospital claims analysis and sizing.	1.50
04/28/20	JD	Review hospital group claims sizing analysis prior to call.	0.60
04/28/20	JD	Review materials provided in response to outstanding	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		diligence questions on the CSR budget and COVID donations.	
04/28/20	IA	Call with M. Huebner (Davis Polk), M. Kesselman, R. Silbert (both Purdue), S. Birnbaum, H. Coleman (both Dechert), J. Turner (PJT), J. DelConte, I. Arana (both AlixPartners) and the Hospital Group re: hospital claims analysis and sizing.	1.50
04/28/20	ADD	Call with PJT re: FTI diligence request list.	0.50
04/28/20	ADD	Review board minutes from 1990 to 1999 to document family member election and resignation dates.	2.70
04/28/20	ADD	Compile data obtained from board materials into spreadsheet with corresponding support.	2.40
04/28/20	ADD	Review data from client's SAP system to identify additional data of interest for diligence request.	2.00
04/29/20	ADD	Call with Davis Polk diligence team re: documents previously produced.	0.20
04/29/20	ADD	Uploaded diligence production from Davis Polk to data room.	1.10
04/29/20	ADD	Review new diligence request list from ad-hoc committee and determine potential sources for requested data.	1.40
04/29/20	ADD	Review debtor board minutes from 1999 - 2017 for third-party confidential information, redacting as appropriate.	3.10
04/29/20	ADD	Draft correspondence to request approval to upload files requested by the UCC to the data room.	0.70
04/29/20	ADD	Review and format materials submitted in response to UCC diligence requests for processing.	1.90
04/30/20	ADD	Update diligence request statistics including compiling number of emails received and number of unique questions for DPW.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
04/30/20	ADD	Review and compile data on the number of virtual data room users at request of DPW.	0.80
04/30/20	ADD	Review and compile materials submitted in response to UCC's diligence requests for processing.	2.70
04/30/20	ADD	Draft correspondence requesting approval to upload documents to the data room.	0.80
04/30/20	ADD	Call with Davis Polk to review outstanding diligence requests in preparation for hearing.	1.00
04/30/20	ADD	Call with PJT re: new diligence requests.	0.50
04/30/20	SJC	Review Sackler titles history.	1.70
04/30/20	JD	Review Sackler family title history to be provided to creditor advisors.	0.30
Total			212.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	174.10	515.00	89,661.50
Nate A Simon	0.20	515.00	103.00
Fernando O Silva	5.10	645.00	3,289.50
Sam J Canniff	1.70	645.00	1,096.50
Isabel Arana de Uriarte	9.10	690.00	6,279.00
Jesse DelConte	22.30	950.00	21,185.00
Total Hours & Fees	212.50		121,614.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
04/08/20	MH	Reconcile the professional payments in the Monthly Operating Report with legal operations.	0.60
04/09/20	MH	Review new orders on professional fees for professional fee tracking.	0.40
04/13/20	MH	Kick off Monthly Operating Report data requests.	0.50
04/13/20	MH	Preparation of accounts payable portion of the insider report for the Monthly Operating Report.	0.90
04/13/20	NAS	Review correspondence and data sources provided by Purdue/TXP for purposes of March 2020 MOR Insider Payments section.	0.30
04/16/20	JD	Review cash balance and spending details to be sent to the UST.	0.20
04/16/20	MH	Update the tracking of professional fee payments for new retained professionals.	0.40
04/16/20	MH	Preparation of summary of cash activity for the Monthly Operating Report including first quarter fee estimates.	0.60
04/19/20	NAS	Correspondence with M. Hartley (AlixPartners) re: insider payments section of March 2020 MOR.	0.10
04/20/20	NAS	Review preliminary draft of insider payments section of March 2020 MOR.	0.60
04/20/20	NAS	Call with M. Hartley, N. Simon (both AlixPartners) to review insider payments section of March 2020 MOR.	0.50
04/20/20	MH	Preparation of insider portion of Monthly Operating Report.	3.90
04/20/20	MH	Call with M. Hartley, N. Simon (both AlixPartners) to review insider payments section of March 2020 MOR.	0.50
04/20/20	MH	Finalize the Monthly Operating Report for March.	1.80
04/20/20	JD	Review draft MOR prior to filing.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
04/20/20	JD	Review updated Avrio business plan numbers.	0.80
04/21/20	NAS	Review final draft of insider payments section of March 2020 MOR.	0.80
04/30/20	MH	Create March report for Ordinary Course Professionals.	3.20
04/30/20	MH	Create final Monthly Operating Report.	1.80
04/30/20	JD	Review final MOR prior to filing.	0.40
04/30/20	JD	Review ordinary course professional payment summary prior to filing.	0.50
Total			19.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Nate A Simon	2.30	515.00	1,184.50
Michael Hartley	14.60	840.00	12,264.00
Jesse DelConte	2.50	950.00	2,375.00
Total Hours & Fees	19.40		15,823.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/01/20	JD	Call with R. Schnitzler, J. Turner (both PJT) and J. Lowne (Purdue) re: Rhodes business plan.	0.30
04/01/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners) re: business plan and Board presentation update.	0.50
04/01/20	JD	Meeting with D. Lundie, D. Fogel, J. Lowne (all Purdue), J. Turner and R. Schnitzler (both PJT) re: Rhodes partnership opportunity.	1.10
04/01/20	JD	Call with D. Lundie, J. Lowne (Purdue), D. Fogel (Purdue), K. McCafferty, J. DelConte, R. Sublett (all AlixPartners) re: partnership discussions.	1.10
04/01/20	JD	Call with J. Turner (PJT) re: business plan presentation.	0.40
04/01/20	JD	Call with J. Lowne (Purdue) re: Rhodes business plan.	0.20
04/01/20	JD	Review comments from M. Kesselman (Purdue) on draft business plan presentation.	1.10
04/01/20	JD	Review updated Rhodes business plan slides from K. McCafferty and R. Sublett (both AlixPartners).	0.80
04/01/20	JD	Review updated Avrio business plan slides.	0.40
04/01/20	JD	Review and comment on updated executive summary slides for the Board presentation.	1.00
04/01/20	JD	Review changes to Adhansia presentation compared against previous version.	0.40
04/01/20	JD	Review comments from management on the Avrio business plan.	0.80
04/01/20	JD	Review correspondence from E. Kardos (AlixPartners) re: Purdue relationships.	0.20
04/01/20	JD	Review and comment on COVID-19 business plan impact slides for the Board presentation.	0.50
04/01/20	DS	Call with head of Finance (Avrio) re: 2018 historical pro	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		forma adjustments.	
04/01/20	NAS	Add check functionality to individual country P&Ls in Mundipharma business plan model.	0.40
04/01/20	NAS	Share findings from individual country P&Ls in Mundipharma business plan model with G. Koch (AlixPartners).	0.40
04/01/20	NAS	Draft discussion topics and supporting information for Mundipharma modeling methodology discussion with advisors involved in diligence process.	2.10
04/01/20	GJK	Preparation of Mundipharma diligence discussion topic list review for advisor call.	0.30
04/01/20	GJK	China review and potential dial drivers of value (up or down).	2.00
04/01/20	GJK	Continue LAM review for diligence.	2.50
04/01/20	GJK	Call with N. Simon, G. Koch (both AlixPartners) re: review findings from individual country P&Ls in Mundipharma business plan model.	0.40
04/01/20	MH	Create accounts payable release file.	0.70
04/01/20	LJD	Call with J. DelConte, L. Donahue (both AlixPartners) re: business plan and Board presentation update.	0.70
04/01/20	LJD	Review and comment on preliminary board presentations.	1.50
04/01/20	LJD	Strategy update call with PJT regarding Adhansia.	0.60
04/01/20	IA	Compare January and March Avrio consumption and market share data to inform performance commentary in Covid context.	1.70
04/01/20	NAS	Draft list of outstanding Mundipharma diligence items by priority level.	0.40
04/01/20	NAS	Incorporate edits from 3/31 discussion with PJT in Mundipharma business plan model.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/01/20	NAS	Revise product categories in Mundipharma business plan model to conform across data sources.	0.60
04/01/20	NAS	Add remaining line items to individual country P&Ls in Mundipharma business plan model.	2.30
04/01/20	IA	Update corporate slides in business plan board presentation based on comments.	2.10
04/01/20	IA	Update Avrio Dashboard slides with tables showing March performance and circulate to Avrio management for commentary.	1.40
04/01/20	KM	Update Rhodes Board deck and implementation plan changes.	1.10
04/01/20	KM	Rhodes turnaround planning -- CPP + forecasting.	0.80
04/01/20	KM	Analysis and review of supply proposal.	0.70
04/01/20	KM	Discussion with D. Fogel (Purdue) and D. Lundie (Purdue) re: partnership options.	0.40
04/01/20	KM	Analysis of partnership options.	0.50
04/01/20	KM	RT cost-volume sensitivity analysis.	0.50
04/01/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: supply analysis.	2.00
04/01/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: partnership discussions.	1.00
04/01/20	KM	Call with D. Lundie, J. Lowne (Purdue), D. Fogel (Purdue), K. McCafferty, J. DelConte, R. Sublett (all AlixPartners) re: partnership discussions.	1.10
04/01/20	KM	Rhodes partnership strategy and impact to budget.	0.40
04/01/20	RDS	Build storyboard for Rhodes section of board presentation and shared updated draft.	2.10
04/01/20	RDS	Review RT partnership follow up materials.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/01/20	RDS	Call with D. Fogel (Purdue) re: partnerships.	0.40
04/01/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: supply analysis.	2.00
04/01/20	RDS	Call with D. Lundie, J. Lowne (Purdue), D. Fogel (Purdue), K. McCafferty, J. DelConte, R. Sublett (all AlixPartners) re: partnership discussions.	1.10
04/01/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: partnership discussions.	1.00
04/01/20	RDS	Preparation for call re: partnerships.	0.40
04/02/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Board deck walk through and call prep.	1.30
04/02/20	KM	Analysis re: strategic plans go forward.	0.40
04/02/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Board deck walk through and call prep.	1.30
04/02/20	KM	RT cost-volume sensitivity analysis.	0.40
04/02/20	KM	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/02/20	KM	Rhodes partnership analysis and outreach.	0.30
04/02/20	KM	Prepare Rhodes strategic analysis.	0.80
04/02/20	KM	Meeting with D. Lundie, J. Lowne (Purdue), R. Shamblen, D. Fogel, J. Doyle (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Partnership analysis and response process.	1.10
04/02/20	KM	Meeting with D. Fogel, R. Haberin (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Pharma stand-alone P&L analysis.	
04/02/20	RDS	Call with D. Fogel (Purdue) re: stand along RP financial profile.	1.30
04/02/20	RDS	Construct strategic diligence list.	0.50
04/02/20	RDS	Meeting with D. Fogel, R. Haberin (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma stand-alone P&L analysis.	1.00
04/02/20	RDS	Review latest updated Purdue board presentation for comments.	0.60
04/02/20	RDS	Respond to questions on Avrio presentations.	0.50
04/02/20	RDS	Changes to updated presentation materials for Project Catalyst.	1.30
04/02/20	RDS	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/02/20	RDS	Update partnership analysis and correspondence with Purdue and Rhodes management team.	0.70
04/02/20	RDS	Meeting with D. Lundie, J. Lowne (Purdue), R. Shamblen, D. Fogel, J. Doyle (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Partnership analysis and response process.	1.10
04/02/20	RDS	Review RP standalone operating financials.	0.60
04/02/20	IA	Update Purdue opex rationalization slide to include updated consolidated numbers and reconciled opex amounts show to the rest of the draft board presentation.	2.20
04/02/20	IA	Validated consumption and market share trend commentary included in Avrio March dashboard slides.	1.20
04/02/20	IA	Review updated board business plan presentation slides.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/02/20	IA	Review Avrio dashboard commentary prepared by management J. Tran and T. Garvey (both Avrio).	1.80
04/02/20	LJD	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/02/20	MH	Create accounts payable release file.	0.70
04/02/20	GJK	Call with I. McClatchy (Norton Rose), update and discuss diligence options.	1.00
04/02/20	GJK	Plan and coordinate advisor diligence	2.00
04/02/20	GJK	Review and analysis of Mundipharma model.	3.00
04/02/20	JD	Review final business plan presentation prior to management meeting. Provide comments re: same.	1.50
04/02/20	JD	Correspondence with R. Schnitzler (PJT) re: Avrio business plan slides.	0.40
04/02/20	JD	Correspondence with R. Sublett and K. McCafferty (both AlixPartners) re: Rhodes business plan updates.	1.20
04/02/20	JD	Call with J. Turner (PJT) re: updated business plan.	0.20
04/02/20	JD	Meeting with C. Landau, M. Kesselman, J. Lowne (all Purdue), T. Coleman, J. O'Connell, J. Turner, R. Schnitzler (all PJT), R. Sublett, K. McCafferty, J. DelConte, L. Donahue (all AlixPartners) re: Board plan presentation.	1.10
04/03/20	JD	Review updated flash report to provide to all parties.	0.60
04/03/20	JD	Review analysis of historical consulting fee payments.	0.40
04/03/20	JD	Review and provide comments on updated Avrio dashboard slides.	0.30
04/03/20	JD	Review and provide comments on updated opex cost slides for the Board presentation.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/03/20	JD	Review and provide comments on latest draft Board business plan presentation.	2.20
04/03/20	JD	Correspondence with R. Aleali (Purdue) and S. Lemack (AlixPartners) re: January flash report and latest MOR.	0.60
04/03/20	JD	Call with J. DelConte, R. Sublett (both AlixPartners) re: Rhodes updated forecast.	0.20
04/03/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.90
04/03/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.50
04/03/20	JD	Call with M. Huebner and E. Vonnegut (both Davis Polk) re: HRT discussions.	0.20
04/03/20	JD	Call with D. Fogel (Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.60
04/03/20	JD	Conversation with J. Turner (PJT) re: Rhodes forecast.	0.20
04/03/20	JD	Meeting with D. Fogel, W. DiNicola, R. Haberin (all Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: updated Rhodes forecast.	1.10
04/03/20	JD	Call with J. Lowne (Purdue) re: Rhodes forecast update.	0.30
04/03/20	GJK	Follow up with B. Bromberg (FTI) re: approach to country diligence in absence of further calls with country managers.	1.90
04/03/20	MH	Create accounts payable release file.	0.70
04/03/20	MH	Add professional firms to AP control process and monthly reporting process.	0.60
04/03/20	LJD	Review business plan iterations.	0.90
04/03/20	IA	Update Avrio dashboard commentary to be discussed with J. Tran (Avrio).	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/03/20	IA	Update case update agenda in preparation for AlixPartners weekly team update call.	0.30
04/03/20	IA	Review latest version of business plan board presentation.	0.80
04/03/20	IA	Reconcile updated consolidated PL numbers and reflected changes in opex rationalization slide.	1.40
04/03/20	IA	Update Avrio dashboard model to reflect comments on market share data and innovation trackers per discussions with Purdue and AlixPartners teams.	2.10
04/03/20	IA	Call with J. Tran (Avrio) re: dashboard slides and March results commentary.	0.50
04/03/20	IA	Call with J. Lowne (Purdue) re: Avrio dashboard slides and March results commentary.	0.20
04/03/20	RDS	Review Rhodes Pharma - RALP consolidated P&L statement.	1.00
04/03/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), R. Sublett, K. McCafferty (both AlixPartners) re: Rhodes Pharma stand-alone financials.	1.60
04/03/20	ADD	Research vendor payment history to prepare for meeting.	2.20
04/03/20	ADD	Compile and prepare files to send to David Polk for review, processing and designation.	1.60
04/03/20	RDS	Reconcile Rhodes Pharma financials and RALP reconciliation.	1.00
04/03/20	RDS	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma and RALP financial reconciliation.	3.80
04/03/20	RDS	Assemble presentation materials to explain the bridge of Rhodes Pharma to RALP consolidation.	1.00
04/03/20	RDS	Update presentation for amended RALP numbers.	2.00
04/03/20	KM	Analysis and review of Rhodes detailed financial	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		reporting.	
04/03/20	KM	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), K. McCafferty (partial attendance), R. Sublett (both AlixPartners) re: Rhodes Pharma and RALP financial reconciliation.	2.10
04/03/20	KM	Rhodes financials tracking.	0.30
04/03/20	KM	Rhodes Board deck re-statement of financial projections.	1.90
04/03/20	KM	Slide edits and analysis re: Rhodes deck for presentation to Purdue Board.	1.80
04/03/20	KM	Financial analysis in support re: Rhodes deck for presentation to Purdue Board.	1.20
04/03/20	KM	Call with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), R. Sublett, K. McCafferty (both AlixPartners) re: Rhodes Pharma stand-alone financials.	1.60
04/03/20	KM	Financial revisions re: Rhodes deck for presentation to Purdue Board.	0.90
04/03/20	KM	Slide edits in support of Rhodes presentation to Purdue Board.	0.50
04/03/20	KM	Meeting with D. Fogel (Purdue) re: Rhodes Pharma and RALP financial restatement.	1.50
04/03/20	RDS	Call with D. Fogel (Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.60
04/03/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.90
04/03/20	RDS	Meeting with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: updated Rhodes forecast.	1.10
04/03/20	RDS	Call with J. DelConte, R. Sublett (both AlixPartners) re: Rhodes updated forecast.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/03/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.50
04/03/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes business plan.	0.50
04/03/20	KM	Call with D. Fogel (Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.60
04/03/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes forecast.	0.90
04/03/20	KM	Meeting with D. Fogel, W. DiNicola, R. Haberlin (all Purdue), J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: updated Rhodes forecast.	1.10
04/04/20	KM	Call with D. Fogel, R. Haberlin (Purdue), R. Sublett (AlixPartners) to tie out manufacturing makeup of Rhodes Pharma gross profit.	0.40
04/04/20	KM	Meeting with D. Fogel, W. DiNicola, R. Haberlin (Purdue), J. Carlisle (Purdue) and R. Sublett (AlixPartners) re: Rhodes Pharma and RALP financials.	2.00
04/04/20	KM	Financial analysis in support of Rhodes deck for presentation to Purdue Board.	0.90
04/04/20	KM	Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes financials for the Board deck.	0.90
04/04/20	RDS	Review Purdue management comments to board presentation draft.	0.30
04/04/20	RDS	Update to underlying RALP budget model to reflect AlixPartners comments.	0.80
04/04/20	RDS	Meeting with D. Fogel, W. DiNicola, R. Haberlin, J. Carlisle (all Purdue) and K. McCafferty (AlixPartners) re: Rhodes Pharma and RALP financials.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/04/20	RDS	Call with D. Fogel, R. Haberin (Purdue), K. McCafferty (AlixPartners) to tie out manufacturing makeup of Rhodes Pharma gross profit.	0.40
04/04/20	RDS	Meeting with D. Fogel, W. DiNicola, R. Haberin, J. Carlisle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes financials for the Board deck.	0.90
04/04/20	RDS	Final PPT changes to reflect PJT and management comments to board slides for Rhodes.	1.30
04/04/20	RDS	Post comments to full PPLP business plan deck.	0.10
04/04/20	RDS	Call with J. Wang (PJT) to articulate estimated savings from plant closure scenario to five-year cash flow.	0.50
04/04/20	ADD	Research vendor payment history to prepare for meeting.	2.50
04/04/20	IA	Provide comments to PJT on Avrio section of business plan presentation ahead of 04/07 meeting.	1.00
04/04/20	IA	Review updated business plan presentation ahead of 04/07 meeting.	0.60
04/04/20	IA	Review restructuring fees tracker for 20% holdback fee payment assumptions.	0.60
04/04/20	LJD	Review schedules and financial bridges for business plan for board meeting next week.	0.90
04/04/20	JD	Review and provide comments on latest draft business plan presentation. Check numbers throughout the presentation.	2.60
04/04/20	JD	Correspondence with J. Turner and R. Schnitzler (both PJT) re: latest draft business plan.	0.50
04/04/20	JD	Review and provide comments on the Rhodes section of the Board presentation.	0.40
04/04/20	JD	Review questions from FTI on the HRT funding request. Review information to be responsive.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/05/20	JD	Review comments on and updated slides re: Adhansia.	0.50
04/05/20	JD	Review correspondence re: Pinney Associates and Purdue history.	0.30
04/05/20	JD	Review comments from E. Ruiz (Purdue) re: Avrio business plan. Review underlying analysis.	0.60
04/05/20	LJD	Review and comment on business plan deck before final send off to board.	1.80
04/05/20	RDS	Review senior management comments to PPLP business plan presentation.	0.40
04/06/20	RDS	Preparation of page-flip questions for the board presentation.	1.30
04/06/20	RDS	Call with D. Fogel (Purdue) on utilization of CPP tool.	0.30
04/06/20	RDS	Meeting with D. Fogel, W. DiNicola (both Purdue) and K. McCafferty (AlixPartners) re: Rhodes Tech stand-alone financials.	1.10
04/06/20	RDS	Updates to board presentation notes for AlixPartners team.	1.40
04/06/20	RDS	Preparation of break-even financial analysis for Rhodes Tech facility sale / supply agreement.	1.90
04/06/20	RDS	Review distributed board presentation.	0.80
04/06/20	RDS	Updates and slide creation for Avrio board presentation.	1.60
04/06/20	KM	Coordination of Rhodes partnership implementation effort.	1.60
04/06/20	KM	R&D program efficiency research and preparation.	2.00
04/06/20	KM	Analysis re: Rhodes R&D re-engineering case for change.	1.20
04/06/20	KM	Meeting with D. Fogel, W. DiNicola (both Purdue) and R. Sublett (AlixPartners) re: Rhodes Tech stand-alone financials.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/06/20	LJD	Prepare for and attend board meeting.	2.10
04/06/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.80
04/06/20	MH	Create accounts payable release file.	0.70
04/06/20	IA	Preparation of updated post-filing voluntary separations report for Purdue and Rhodes.	0.80
04/06/20	IA	Call with J. Tran (Purdue) re: questions and comments received from J. Lowne (Purdue) on business plan slides to be presented to the board.	0.40
04/06/20	IA	Call re: HRT agreement with committees.	0.70
04/06/20	IA	Call with J. Turner, R. Schnitzler (PJT), J. Lowne, J. Tran (Purdue), J. DelConte, I. Arana (both AlixPartners) re: Avrio business plan board presentation.	0.70
04/06/20	JD	Call with R. Aleali (Purdue) re: board presentation.	0.40
04/06/20	JD	Call with C. Robertson (Davis Polk) re: HRT diligence questions.	0.20
04/06/20	JD	Call with R. Aleali (Purdue) re: HRT diligence.	0.20
04/06/20	JD	Prepare for and participate in a call with all committee advisors, state AG's, Davis Polk, PJT and J. DelConte, I. Arana (both AlixPartners) re: HRT diligence questions.	1.00
04/06/20	JD	Preparation for and participate in Purdue Board meeting.	2.00
04/06/20	JD	Review Avrio business plan presentation prior to preparation call.	0.50
04/06/20	JD	Call with J. Turner, R. Schnitzler (PJT), J. Lowne, J. Tran (Purdue), J. DelConte, I. Arana (both AlixPartners) re: Avrio business plan board presentation.	0.70
04/06/20	JD	Correspondence with C. Robertson (Davis Polk) re: HRT diligence questions.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/06/20	JD	Research Oncology business plan spending and questions re: board presentation. Correspondence with R. Aleali and E. Ruiz (both Purdue) re: same.	0.80
04/06/20	GJK	Discussion with N. Simon (AlixPartners) re: goals for 4/7 call with other Mundipharma diligence advisors and key discussion topics.	0.40
04/06/20	GJK	Review OxyContin market for Mundipharma advisor call prep.	3.00
04/06/20	GJK	Preparation for advisor discussion re: China and ANZ projections.	2.00
04/06/20	NAS	Discussion with G. Koch (AlixPartners) re: goals for 4/7 call with other Mundipharma diligence advisors and key discussion topics.	0.40
04/06/20	NAS	Review initial draft of Mundipharma diligence report outline provided by PJT.	0.50
04/06/20	NAS	Outline Mundipharma diligence priorities for week of April 6th.	0.80
04/06/20	NAS	Review new Mundipharma diligence documents and responses provided by Huron.	1.30
04/06/20	NAS	Review Mundipharma IQVIA data and compare to price/volume projections provided by management.	1.90
04/06/20	NAS	Draft discussion points for diligence update call with other advisors involved in Mundipharma diligence process.	1.70
04/06/20	GJK	Calls with N. Simon (AlixPartners) re: diligence process including preparation for Review IQvia data feedback.	0.40
04/07/20	GJK	Discussion with N. Simon, G. Koch (both AlixPartners), other debtor advisors, AHC advisors, and UCC advisors re: Mundipharma diligence methodology.	1.00
04/07/20	GJK	Call with N. Simon (AlixPartners) to prepare for	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma diligence methodology discussion with debtor advisors - AlixPartners and PJT, AHC advisors - FTI and HL, UCC advisors - Province and Jefferies.	
04/07/20	GJK	Review diligence document and diligence planning post Advisor call.	2.50
04/07/20	GJK	Review price x volume and forecast planning.	1.60
04/07/20	NAS	Review draft of Mundipharma report outline provided by PJT and provide feedback.	0.80
04/07/20	NAS	Review responses provided by Huron to Mundipharma diligence questions.	0.40
04/07/20	NAS	Prepare for Mundipharma diligence methodology discussion with other debtor advisors - AlixPartners and PJT, AHC advisors - FTI and HL, UCC advisors - Province and Jefferies.	1.20
04/07/20	NAS	Call with G. Koch (AlixPartners) to prepare for Mundipharma diligence methodology discussion with debtor advisors - AlixPartners and PJT, AHC advisors - FTI and HL, UCC advisors - Province and Jefferies.	1.30
04/07/20	NAS	Discussion with N. Simon, G. Koch (both AlixPartners), other debtor advisors, AHC advisors, and UCC advisors re: Mundipharma diligence methodology.	1.00
04/07/20	NAS	Follow up items (including request list and key takeaways) following Mundipharma methodology discussion with advisors to debtor, AHC, and UCC.	0.90
04/07/20	NAS	Call with J. Arsic (PJT) to provide background on Mundipharma diligence process and divide responsibilities for sections of interim report.	0.90
04/07/20	NAS	Add additional KPIs (e.g. growth rates, ratios) to Mundipharma business plan model.	1.30
04/07/20	JD	Prepare for and participate in Purdue Board meeting.	6.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/07/20	JD	Conversation with R. Aleali (Purdue) re: post Board meeting follow up.	0.40
04/07/20	JD	Review and write up notes prior to board call.	1.00
04/07/20	IA	Review final draft of business plan presentation to the board.	1.30
04/07/20	MH	Create accounts payable release file.	0.70
04/07/20	MH	Update legal release files and OCP control files based on revised information from legal operations.	1.40
04/07/20	LJD	Prepare for and attend Purdue board meeting.	7.20
04/07/20	MH	Respond to client questions about prepetition for a marketing vendor.	0.40
04/07/20	KM	Rhodes next phase implementation planning.	1.30
04/07/20	KM	Rhodes R&D project slip-chart analysis.	0.70
04/07/20	KM	Rhodes R&D re-engineering approach development.	1.00
04/07/20	KM	Purdue Board meeting re: Rhodes and Avrio business plans.	0.60
04/07/20	KM	Analysis re: Rhodes pipeline forecasting.	1.00
04/07/20	KM	Call with D. Lundie (Purdue) and R. Sublett (AlixPartners) re: Rhodes next phase transformation.	1.10
04/07/20	KM	Rhodes R&D and Financial re-engineering roadmap development.	0.90
04/07/20	KM	Deck development re: Rhodes R&D restructuring roll-out.	0.70
04/07/20	RDS	Call with D. Lundie (Purdue), K. McCafferty (AlixPartners) re: Rhodes next phase transformation.	1.10
04/07/20	RDS	Construct materials to update management on current work stream progress and next steps.	1.10
04/07/20	RDS	Review and prepare materials for an R&D turnaround effort at Rhodes.	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/07/20	RDS	Purdue Board meeting for RALP and Avrio presentation points.	1.80
04/07/20	RDS	Analysis of Avrio business plan changes.	0.70
04/08/20	RDS	Preparation of materials for FP&A transformation at Rhodes.	0.60
04/08/20	RDS	Call with D. Fogel, W. DiNicola (both Purdue), K. McCafferty (AlixPartners) re: Rhodes Tech P&L breakdown for stand-alone financials.	1.20
04/08/20	RDS	Amend historical and forecast Rhodes Tech revenues to conform to true third-party pricing.	1.10
04/08/20	RDS	Construct product development committee meeting presentation slides.	2.00
04/08/20	RDS	Call with D. Fogel, W. DiNicola (both Purdue), K. McCafferty (AlixPartners) re: Rhodes Tech standalone financials.	1.00
04/08/20	RDS	Assemble budget model for standalone Rhodes Tech plant.	1.40
04/08/20	RDS	Review Rhodes Tech intercompany allocations and alternative suggested costs.	1.40
04/08/20	RDS	Review of Project Catalyst materials.	0.40
04/08/20	KM	Rhodes next phase implementation planning.	0.60
04/08/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) and R. Sublett (AlixPartners) re: Rhodes Tech P&L breakdown for stand-alone financials.	1.20
04/08/20	KM	Analysis re: Rhodes Tech past/forecast financials for partnership discussions.	1.00
04/08/20	KM	R&D process re-engineering process development and discussion with AlixPartners SMEs.	0.60
04/08/20	KM	Continue analysis re: Rhodes Tech past/forecast financials	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		for partnership discussions.	
04/08/20	KM	Analysis re: Rhodes Tech P&L breakdown for stand-alone financials.	0.40
04/08/20	KM	Call with D. Fogel, W. DiNicola (both Purdue) and R. Sublett (AlixPartners) re: Rhodes Tech standalone financials.	1.00
04/08/20	MH	Create accounts payable release file.	0.70
04/08/20	LJD	Update call with J. Dubel (Purdue) and L. Donahue (AlixPartners).	0.50
04/08/20	IA	Review updated Purdue and Rhodes weekly sales reports to be sent to management for review.	0.80
04/08/20	IA	Call with J Turner, R Schnitzler (both PJT) and I. Arana, J. DelConte (both AlixPartners) re: creditor business plan presentation.	0.50
04/08/20	IA	Review customer programs report for February.	1.10
04/08/20	IA	Provide comments and a proposed outline for creditor business plan presentation based on board presentation.	2.90
04/08/20	HK	Update IAC diligence tracker with additions to the diligence data site.	2.50
04/08/20	JD	Call with J Turner, R Schnitzler (both PJT) and I. Arana, J. DelConte (both AlixPartners) re: creditor business plan presentation.	0.50
04/08/20	JD	Correspondence with R. Brown (Purdue) re: professional fee accruals for March.	0.70
04/08/20	JD	Review and provide comments on latest weekly sales reports.	0.40
04/08/20	JD	Review and make notes on the first cut of the creditor presentation outline from PJT.	1.10
04/08/20	JD	Review latest IMS data pulls prior to sharing with	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		creditors.	
04/08/20	JD	Partial review draft board materials prior to them being shared with various creditor advisors.	0.70
04/08/20	JD	Review board presentation in order to determine what work needs to be done to convert it to a creditor advisor presentation.	2.10
04/08/20	JD	Review and provide comments on the latest customer report.	0.60
04/08/20	JD	Preparation of analysis of costs for contract assumption.	0.80
04/08/20	JD	Review correspondence from J. Lowne and J. Tran (both Purdue) re: Avrio Board follow up questions.	0.30
04/08/20	NAS	Draft to-do list with respect to Mundipharma business plan model and requested diligence items.	0.40
04/08/20	NAS	Translate Mundipharma cash flow information (provided by management) from a legal entity basis to a region/functional basis to assess liquidity profile.	2.40
04/08/20	NAS	Discussion with G. Koch (AlixPartners) re: revisions to Mundipharma business plan model.	0.90
04/08/20	NAS	Draft findings from analysis of Mundipharma cash flow information and provide for G. Koch (AlixPartners).	0.80
04/08/20	NAS	Add additional growth and profitability metrics to all scenarios in Mundipharma business plan model.	2.20
04/08/20	NAS	Prepare for call with PJT re: interim report outline and other deliverables.	0.40
04/08/20	NAS	Call with G. Koch (AlixPartners), J. Turner, R. Schnitzler, and J. Arsic (all PJT) re: interim report outline and other deliverables.	0.70
04/08/20	NAS	Discussion with G. Koch (AlixPartners) to review analysis of Mundipharma cash flow information and share	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		takeaways from call with PJT.	
04/08/20	GJK	Discussion with N. Simon (AlixPartners) to review analysis of Mundipharma cash flow information and share takeaways from call with PJT.	0.50
04/08/20	GJK	Call with N. Simon (AlixPartners), J. Turner, R. Schnitzler, and J. Arsic (all PJT) re: interim report outline and other deliverables.	0.70
04/08/20	GJK	Discussion with N. Simon (AlixPartners) regarding revisions to Mundipharma business plan model.	0.90
04/08/20	GJK	Review cash flows analysis.	1.20
04/08/20	GJK	Conduct Mundipharma markets diligence/balance sheet and VDD.	2.00
04/08/20	GJK	Plan for Mundipharma diligence including preparation for team call.	1.50
04/09/20	GJK	Review cost allocation.	0.30
04/09/20	GJK	Mundipharma diligence coordination and planning.	1.00
04/09/20	NAS	Prioritize revisions to Mundipharma model and other follow-ups from 4/8 discussion with PJT.	0.70
04/09/20	NAS	Review prior materials created re: key Mundipharma products to provide overview for PJT.	0.50
04/09/20	NAS	Review EY Mundipharma VDD report in order to classify costs in P&L as variable or fixed for model.	1.40
04/09/20	NAS	Update revised sales scenario in Mundipharma model to be dynamic with respect to fixed/variable cost toggles.	2.50
04/09/20	NAS	Review Mundipharma market-level diligence questions sent by FTI.	0.40
04/09/20	NAS	Build check functionality in Mundipharma model for revised sales case with fixed/variable cost toggles.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/09/20	NAS	Update region standalone scenario in Mundipharma model to use new sales case methodology instead of 2020 original budget.	1.30
04/09/20	GJK	Meeting with J. DelConte, M. Hartley, L. Donahue (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	0.40
04/09/20	GJK	Review China diligence.	2.50
04/09/20	GJK	Draft China market diligence questions.	2.50
04/09/20	GJK	Calls with N. Simon (AlixPartners) re: diligence coordination.	0.40
04/09/20	JD	Review Avrio overview presentation provided to the Board as follow up to the business plan presentation.	0.60
04/09/20	JD	Call with J. Lowne (Purdue) re: cost allocations.	0.30
04/09/20	JD	Continue review of draft board materials to provide to creditors.	1.50
04/09/20	JD	Call with C. Robertson (Davis Polk) re: asset sale procedures and HRT contract diligence.	0.40
04/09/20	JD	Correspondence with R. Aleali (Purdue) and T. Melvin (PJT) re: DOJ requests.	0.50
04/09/20	JD	Finalize contract assumption calculations.	0.30
04/09/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.30
04/09/20	IA	Incorporate comments from PJT and AlixPartners to creditor business plan presentation to be discussed with management.	1.90
04/09/20	IA	Consolidate PJT and AlixPartners comments to business plan presentation to create creditor draft.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/09/20	IA	Review operational scorecard slide update for February flash report.	0.60
04/09/20	IA	Review management comments to latest cash report and forecast for week ended 03/27.	0.60
04/09/20	IA	Review PJT comments to business plan presentation to create creditor draft.	1.40
04/09/20	NAS	Calls with G. Koch (AlixPartners) re: diligence coordination.	0.40
04/09/20	LJD	Prepare for and attend meeting with G. Koch, M. Hartley, J. DelConte (AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, C. Robertson (both Davis Polk), J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case update and go forward next steps.	0.70
04/09/20	LJD	Review Avrio updated presentation.	0.60
04/09/20	MH	Reconcile payments to approved critical vendor to determine treatment of new prepetition invoice.	0.50
04/09/20	MH	Create accounts payable release file.	0.70
04/09/20	KM	Analysis of partnership opportunities.	2.00
04/09/20	KM	Analysis re: RT stand-alone financials.	2.60
04/09/20	KM	Project Catalyst slide preparation	0.60
04/09/20	KM	Call with D. Fogel, R. Haberin, W. DiNicola, N. Davis, J. Carlisle (all Purdue) and R. Sublett (AlixPartners) re: next phase CPP analysis.	1.00
04/09/20	KM	Call with D. Fogel, W. DiNicola (both Purdue), R. Sublett (AlixPartners) re: RT stand alone financials.	1.60
04/09/20	KM	Continue analysis re: RT stand-alone financials.	0.20
04/09/20	KM	Analysis and presentations re: partnership opportunities.	1.40
04/09/20	RDS	Assemble presentation on generic product development	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		best practices.	
04/09/20	RDS	Call with D. Fogel (Purdue) re: supply options.	2.30
04/09/20	RDS	Construction of a stand-alone API manufacturing plant financial model.	2.20
04/09/20	RDS	Create model for different strategic options.	1.30
04/09/20	RDS	Create presentation for management of differing go forward strategic options.	1.90
04/09/20	RDS	Call with D. Fogel, R. Haberin, W. DiNicola, N. Davis, J. Carlisle (all Purdue), K. McCafferty (AlixPartners) re: next phase CPP analysis.	1.00
04/09/20	RDS	Call with D. Fogel, W. DiNicola (both Purdue), K. McCafferty (AlixPartners) re: RT stand alone financials.	1.60
04/10/20	RDS	Correspondence with D. Fogel (Purdue) re: strategic planning.	0.30
04/10/20	RDS	Call with D. Lundie, D. Fogel, J. Lowne, P. Strassburger, J. Doyle R. Shamblen, R. Aleali (all Purdue), R. Sublett, J. DelConte, K. McCafferty (all AlixPartners), J. Turner, R. Schnitzler (both PJT) re: Project Catalyst.	2.00
04/10/20	RDS	Preparation of Rhodes finance transformation.	1.30
04/10/20	RDS	Review of COVID response at Rhodes in the scope of GE pharmaceuticals.	0.50
04/10/20	RDS	Aggregate forecast volume data.	0.30
04/10/20	KM	Meeting with R. Shamblen (Purdue) re: review AlixPartners slides for Project Catalyst meeting.	0.30
04/10/20	KM	Analysis and slide preparation re: Project Catalyst meeting.	1.00
04/10/20	KM	Call with D. Lundie, D. Fogel, J. Lowne, P. Strassburger, J. Doyle R. Shamblen, R. Aleali (all Purdue), R. Sublett, J. DelConte, K. McCafferty (all AlixPartners), J. Turner, R.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Schnitzler (both PJT) re: Project Catalyst.	
04/10/20	KM	Analysis re: Project Catalyst.	0.20
04/10/20	KM	Meeting with D. Fogel (Purdue) re: strategic planning.	0.10
04/10/20	MH	Create monthly analysis of open prepetition balances not eligible for payment under motion.	1.00
04/10/20	MH	Create accounts payable release file.	0.70
04/10/20	LJD	Debrief call with K. Buckfire (Board member) re: board meeting.	0.60
04/10/20	LJD	Review staffing needs.	0.30
04/10/20	LJD	Call with J. Dubel (Board Member) re: subsidiaries and allocation methodology.	0.70
04/10/20	LJD	Review correspondence and analysis re: allocation of shared services and subsidiary costs.	0.90
04/10/20	NAS	Calls with G. Koch (AlixPartners) on coordination and model priorities.	0.30
04/10/20	IA	Call with R. Aleali (Purdue), J. DelConte, I. Arana (both AlixPartners) re: creditor business plan presentation.	1.00
04/10/20	IA	Follow up with Purdue Legal on specific slides containing third party data that are included in creditor business plan presentation.	0.80
04/10/20	IA	Incorporate comments from PJT and AlixPartners to creditor business plan presentation to be discussed with management.	1.20
04/10/20	IA	Call with C DeStefano (Purdue) re: 2020 to 2022 LTRP payments bridge detail to support business plan presentation.	0.50
04/10/20	JD	Review article re: opioid shortages and correspondence with J. Lowne (Purdue) and R. Sublett (AlixPartners) re: same.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/10/20	JD	Review correspondence from J. Lowne (Purdue) re: LTRP details. Review details re: same.	0.50
04/10/20	JD	Review correspondence between J. Turner (PJT) and J. Lowne (Purdue) re: cost allocation.	0.30
04/10/20	JD	Review 2004 discovery motion and subpoena.	0.40
04/10/20	JD	Review latest version of the creditor business plan presentation.	0.70
04/10/20	JD	Review inbound interested parties log.	0.30
04/10/20	JD	Partial participation in call with D. Lundie, D. Fogel, J. Lowne, P. Strassburger, J. Doyle R. Shamblen, R. Aleali (all Purdue), R. Sublett, J. DelConte, K. McCafferty (all AlixPartners), J. Turner, R. Schnitzler (both PJT) re: Project Catalyst.	1.10
04/10/20	JD	Call with R. Aleali (Purdue), J. DelConte, I. Arana (both AlixPartners) re: creditor business plan presentation.	1.00
04/10/20	GJK	Calls with N. Simon (AlixPartners) on coordination and model priorities.	0.30
04/10/20	NAS	Review market-level Mundipharma diligence questions drafted by G. Koch (AlixPartners) and suggest additions.	1.10
04/10/20	NAS	Draft weekly update for Mundipharma diligence workstream and prepare for AlixPartners engagement team update call.	0.90
04/10/20	NAS	Modify Mundipharma business plan model for scenarios to consider March 2020 sales update provided by management.	1.10
04/10/20	GJK	Continue review of diligence questions for Europe, including call/email exchange with B. Bromberg (FTI).	2.00
04/10/20	GJK	Review Canada and Europe (continued) for Mundipharma diligence.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/11/20	LJD	Call with board members regarding revised reporting for subsidiary cash flows and balance sheets.	1.20
04/12/20	RDS	Work toward consolidated financial plan.	0.10
04/12/20	RDS	Update board level KPI reporting formatting for March actuals.	0.80
04/12/20	RDS	Correspondence with D. Fogel (Purdue) re: latest consolidated RALP financial presentation for April business plan board meeting.	0.30
04/13/20	RDS	Call with N. Davis (Purdue), K. McCafferty (AlixPartners) re: latest turnaround implementation plan and monthly dashboard.	0.30
04/13/20	RDS	Call with D. Fogel (Purdue) re: Project Windsor financial update.	0.20
04/13/20	RDS	Edits to Project Catalyst teaser materials.	1.40
04/13/20	RDS	Update March dashboard implementation progress tracker.	1.10
04/13/20	RDS	Preparation of materials for portfolio review meeting with D. Lundie (Purdue).	1.50
04/13/20	RDS	Call re: consolidated PPLP consolidated budget with D. Fogel, W. DiNicola, R. Haberin (all Purdue), T. Melvin, G. Sim (both PJT), K. McCafferty (AlixPartners).	0.40
04/13/20	KM	Rhodes implementation plan review.	0.60
04/13/20	KM	Rhodes R&D and pipeline re-engineering requirements.	1.30
04/13/20	KM	Analysis re: Rhodes Tech volume forecast.	0.70
04/13/20	KM	Analysis re: Rhodes CPP expansion.	0.90
04/13/20	KM	Analysis re: Rhodes personnel and reporting, spans and layers analysis refresh.	1.10
04/13/20	KM	Call re: consolidated PPLP consolidated budget with D.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Fogel, W. DiNicola, R. Haberin (all Purdue), T. Melvin, G. Sim (both PJT), R. Sublett (AlixPartners).	
04/13/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
04/13/20	KM	Meeting with N. Davis (Purdue) and R. Sublett (AlixPartners) re: implementation dashboard.	0.30
04/13/20	KM	Preparation of the March Rhodes implementation dashboard.	1.10
04/13/20	LJD	Prepare for and attend call with J. Lowne (Purdue), T. Coleman, J. O'Connell, J. Turner (PJT), J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.70
04/13/20	LJD	Prepare for call with AP team in advance of call with management on Monday.	0.30
04/13/20	LJD	Call with T. Coleman, R. Schnitzler, J. Turner (PJT), B. Bartell, S. Lyman (Duff & Phelps) and J. DelConte (AlixPartners) re: strategic plans.	1.10
04/13/20	LJD	Review and edit fee app.	0.30
04/13/20	LJD	Call with J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.20
04/13/20	MH	Update vendor release list with new trade agreement.	0.40
04/13/20	MH	Create accounts payable release file.	0.70
04/13/20	IA	Follow up on third party consent to share third party product analytics for Avrio.	0.60
04/13/20	GJK	Review of S. Jamieson responses and files to diligence question.	2.80
04/13/20	GJK	Review advisor questions and analysis.	2.50
04/13/20	GJK	Coordinate and plan for Mundipharma diligence report.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/13/20	NAS	Review Mundipharma diligence questions drafted by FTI and revise additional follow-up questions drafted by G. Koch (AlixPartners).	1.50
04/13/20	NAS	Draft list of Mundipharma diligence priority items for week of April 13th.	0.20
04/13/20	NAS	Build check functionality for region standalone scenarios in Mundipharma business plan model and resolve discrepancy.	1.20
04/13/20	NAS	Build check functionality in Mundipharma business plan model for revised product line standalone cases following March 2020 sales update.	0.80
04/13/20	NAS	Build additional product line standalone cases in Mundipharma business plan model for Biosimilars, Diabetes, Oncology, Respiratory, and Other Ethical business lines.	2.60
04/13/20	NAS	Revise product line standalone cases in Mundipharma business plan model to reflect March 2020 sales update and corresponding allocation methodology.	2.10
04/13/20	JD	Call with T. Coleman, R. Schnitzler, J. Turner (PJT), B. Bartell, S. Lyman (Duff & Phelps) and L. Donahue (AlixPartners) re: strategic plans.	1.10
04/13/20	JD	Call with J. Lowne (Purdue), T. Coleman, J. O'Connell, J. Turner (PJT), J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.50
04/13/20	JD	Call with J. Lowne (Purdue) re: business plan follow ups and creditor presentation.	0.20
04/13/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners) re: board meeting follow ups.	0.20
04/13/20	JD	Review strategic side by side analysis prior to call with Duff and Phelps.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/13/20	JD	Review and provide comments on February flash report. Compare report against last month's report.	1.80
04/13/20	JD	Research federal and state funding of Naloxone and other opioid antagonists.	2.00
04/14/20	JD	Review materials in advance of this morning's board meeting.	0.50
04/14/20	JD	Participate in PPI board meeting.	1.00
04/14/20	JD	Call with J. Turner (PJT) re: post-board meeting follow up.	0.20
04/14/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes next steps.	0.40
04/14/20	JD	Review diligence request from FTI and associated files.	0.70
04/14/20	JD	Review analysis of year over year changes in bonus compensation structures and amounts.	0.80
04/14/20	JD	Review final Nalmafene report per court filing.	0.20
04/14/20	JD	Review finance and R&D re-engineering proposal for Rhodes.	0.60
04/14/20	NAS	Revise standalone Consumer Health and Ethical P&Ls in Mundipharma business plan model to reference March 2020 sales update.	2.30
04/14/20	NAS	Review latest draft of Mundipharma business plan model with G. Koch (AlixPartners) and discuss next steps for diligence report.	1.40
04/14/20	NAS	Brainstorm structure of Mundipharma Ethical business overview presentation for PJT.	1.00
04/14/20	NAS	Draft Mundipharma Ethical business overview presentation for PJT.	2.70
04/14/20	GJK	Review latest draft of Mundipharma business plan model with N. Simon (AlixPartners) and discuss next steps for	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence report.	
04/14/20	GJK	Coordination of Mundipharma diligence including follow ups and email exchanges with larger advisory group.	2.00
04/14/20	GJK	Analysis of updates from Mundipharma diligence questions.	2.80
04/14/20	IA	Draft LTRP 2020 to 2022 payments bridges for Rhodes to support long term plan forecast.	1.30
04/14/20	IA	Summarize projected LTRP 2020 to 2022 payments by employee for Purdue and Rhodes and reconciled to Finance accrual amounts.	2.60
04/14/20	IA	Draft LTRP 2020 to 2022 payment bridges to support payment assumptions in long term plan forecast.	1.70
04/14/20	IA	Review OCP monthly reporting process and reports in preparation for transition call with AlixPartners team.	0.80
04/14/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.40
04/14/20	MH	Adjust automatic accounts payable hold lists to reflect updated risk assessment.	0.90
04/14/20	MH	Create accounts payable release file.	0.70
04/14/20	LJD	Prepare for and attend board meeting.	1.20
04/14/20	LJD	Call with J. Dubel (Purdue) re: debriefing	0.60
04/14/20	LJD	Review and discuss Rhodes workplan with team.	0.90
04/14/20	KM	Finance re-engineering workplan development.	0.80
04/14/20	KM	R&D re-engineering workplan development.	0.70
04/14/20	KM	Analysis re: Rhodes personnel.	0.30
04/14/20	KM	Analysis re: Rhodes Pharma product launch plans.	1.00
04/14/20	KM	Analysis re: Rhodes reporting spans and layers.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/14/20	KM	Slides for Rhodes product launch plan.	0.80
04/14/20	KM	Call with D. Fogel, N. Davis (both Purdue), R. Sublett (AlixPartners) re: updated dashboard.	1.40
04/14/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes next steps.	0.40
04/14/20	RDS	Assemble scope and overview of process implementation for product development and finance transformation.	1.50
04/14/20	RDS	Communication of strategy for FP&A and product development implementations.	0.60
04/14/20	RDS	Assemble teaser for Rhodes Pharma and Wilson sites.	1.90
04/14/20	RDS	Call with D. Fogel, N. Davis (both Purdue), K. McCafferty (AlixPartners) re: updated dashboard.	1.40
04/14/20	RDS	Updates to work plan for Rhodes turnaround implementation plan.	0.30
04/14/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: Rhodes next steps.	0.40
04/15/20	RDS	Review of teaser documentation.	0.70
04/15/20	RDS	Update PMO plan for Rhodes initiatives.	0.20
04/15/20	RDS	Implement changes to Rhodes and Avrio dashboards.	1.10
04/15/20	KM	Rhodes Dashboard.	1.10
04/15/20	KM	Rhodes turnaround initiatives program management.	0.90
04/15/20	LJD	Call with K. Buckfire (Board member)	0.70
04/15/20	LJD	Coordination call with PJT.	0.50
04/15/20	MH	Release new critical vendor for accounts payable.	0.40
04/15/20	MH	Create accounts payable release file.	0.70
04/15/20	HK	Update IAC diligence tracker with additions to the diligence data site.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/15/20	IA	Update board business plan presentation materials to be shared with creditors.	2.10
04/15/20	IA	Call with C DeStefano and J. Lowne (both Purdue) re: 2020 to 2022 LTRP bridges to support budget financials.	0.40
04/15/20	IA	Update LTRP 2020 bridges to include comments from management and reconciled amounts to latest tracker.	1.30
04/15/20	GJK	PV analysis and exchanges based on N. Simon (AlixPartners) analysis.	2.40
04/15/20	GJK	Draft follow up email with Advisors to Mundipharma re: open diligence items.	0.40
04/15/20	NAS	Prioritize Mundipharma diligence requests currently outstanding.	0.50
04/15/20	NAS	Review new diligence files provided by Mundipharma and Huron on 4/10, 4/13, and 4/14.	2.00
04/15/20	NAS	Analysis of 2019 price/volume information provided by Mundipharma to establish baseline for 2020-2024 projections.	2.60
04/15/20	NAS	Begin update of individual country P&Ls in Mundipharma business plan model to use March 2020 revised sales case.	0.30
04/15/20	JD	Call with J. Lowne, D. Fogel and D. Lundie (all Purdue) re: Rhodes dashboard.	0.50
04/15/20	JD	Review draft Rhodes dashboard.	0.60
04/15/20	JD	Preparation of draft agenda for review for tomorrow morning's call with DPW, PJT, AlixPartners and the company.	0.50
04/15/20	JD	Review comments from R. Aleali (Purdue) re: proposed board materials to be shared. Review draft board materials along with comments.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/15/20	JD	Review Nielsen data and agreement to determine what can be shared with third parties.	0.70
04/15/20	JD	Review latest draft presentation to provide to the various creditor groups re: updated business plan. Provide comments re: same.	2.30
04/16/20	JD	Review updated incentive compensation bridges.	0.30
04/16/20	JD	Correspondence with D. Rosen (Purdue) and K. Benedict (Davis Polk) re: RxPricing information and ability to share.	0.70
04/16/20	JD	Update case professional fee tracker for recently filed fee applications. Compare to budget and update YTD trend.	0.80
04/16/20	JD	Review new batch of minutes and resolutions to be shared with the various creditor advisors.	1.30
04/16/20	JD	Review updated information re: Purdue pension plan performance.	0.60
04/16/20	JD	Review consolidated financial statements provided by E. Ruiz (Purdue) to be included in the dynamic financial model.	1.00
04/16/20	JD	Call with J. Lowne and M. Ronning (both Purdue) re: Adhansia board update.	0.50
04/16/20	JD	Review non-consenting state subpoena.	0.30
04/16/20	NAS	Coordination with J. Arsic (PJT) re: draft of Mundipharma diligence report.	0.70
04/16/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma Ethical overview presentation for PJT and takeaways from new diligence files provided.	0.70
04/16/20	NAS	Revise overview of Mundipharma Ethical business following discussion with G. Koch (AlixPartners) and prepare supporting materials for PJT.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/16/20	NAS	Discussion with G. Koch (AlixPartners) re: current status of Mundipharma diligence process.	0.40
04/16/20	NAS	Review source data (Mundipharma Board/budget books) for assumptions around net working capital (DSO and DIOH).	0.90
04/16/20	NAS	Project Mundipharma accounts receivable by market cluster using DSO assumptions and revenue projections from business plan model.	1.20
04/16/20	NAS	Project Mundipharma inventory by market cluster using DIOH assumptions and COGS projections from business plan model.	1.30
04/16/20	GJK	Call with N. Simon (AlixPartners) re: current status of Mundipharma diligence process.	0.40
04/16/20	GJK	Analysis of Mundipharma 2019A vs 2019 YEE comparison.	2.00
04/16/20	GJK	Review of Mundipharma NWC based on N. Simon (AlixPartners) analysis and VDD.	1.00
04/16/20	GJK	Call with I. McClatchy (Norton Rose) re Mundipharma - overall diligence process.	1.00
04/16/20	GJK	Discussion with N. Simon (AlixPartners) regarding Mundipharma Ethical overview presentation for PJT and takeaways from new diligence files provided.	0.70
04/16/20	GJK	Call with B. Bromberg (FTI) re: Mundipharma diligence.	0.30
04/16/20	GJK	Analysis of Mundipharma P&L.	2.50
04/16/20	IA	Meeting with M. Hartley, I. Arana, S. Lemack (all AlixPartners) re: professional payment tracking process.	0.50
04/16/20	NAS	Preliminary assessment of Mundipharma days payable outstanding using accounts payable data on legal entity balance sheets.	0.70
04/16/20	NAS	Share current status of and preliminary findings from net	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		working capital (DSO, DIOH, DPO) with G. Koch (AlixPartners).	
04/16/20	SKL	Meeting with M. Hartley, I. Arana, S. Lemack (all AlixPartners) re: professional payment tracking process.	0.50
04/16/20	IA	Reconcile 2020 to 2023 amounts submitted by Purdue to finance using latest version of LTRP trackers for payments by employee.	1.40
04/16/20	IA	Update LTRP 2020-2020 Purdue and Rhodes bridges to reflect comments from Purdue management.	0.90
04/16/20	IA	Review consolidated financials for 2020 April budget file with PL allocations by segment to be incorporated to draft creditor presentation.	2.20
04/16/20	IA	Format consolidated and segment financials to be included in creditor draft presentation slides.	1.80
04/16/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: accounts payable and critical vendor process.	0.60
04/16/20	MH	Meeting with M. Hartley, I. Arana, S. Lemack (all AlixPartners) re: professional payment tracking process.	0.50
04/16/20	MH	Create accounts payable release file.	0.70
04/16/20	LJD	Prepare for and participate in call with E. Vonnegut, T. Graulich (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), L. Donahue, J. DelConte (both AlixPartners) re: case update and team coordination.	1.30
04/16/20	KM	Analysis re: Rhodes Tech filings and COA for partnership discussions.	0.50
04/16/20	KM	Meeting with D. Fogel, W. DiNicola (Purdue) and R. Sublett (AlixPartners) re: stand alone RT financials.	1.30
04/16/20	KM	Document preparation re: strategic options with updated	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		volumes and financials.	
04/16/20	KM	RT volume breakdown and COA alignment.	1.80
04/16/20	RDS	Correspondence with Rhodes management team about asset teaser.	0.80
04/16/20	RDS	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty (AlixPartners).	1.30
04/16/20	RDS	Update teaser presentation for latest financial information.	1.10
04/17/20	RDS	Update presentation for latest financial information.	0.80
04/17/20	KM	Meeting with R. Shamblen and S. Yates (both Purdue) re: Forecast RT volume and associates COAs.	1.00
04/17/20	KM	Analysis re: forecast RT volume.	0.30
04/17/20	KM	Analysis re: forecast RT volume.	0.40
04/17/20	KM	Rhodes implementation planning - Rhodes CPP.	0.40
04/17/20	LJD	Update call with K. Buckfire (Board member)	0.40
04/17/20	LJD	Coordination call with PJT.	0.60
04/17/20	MH	Create accounts payable release file.	0.70
04/17/20	MH	Evaluate vendor invoice for sales team bonuses to determine petition status.	0.60
04/17/20	MH	Create an action map for accounts payable controls to document correct actions for each event.	0.70
04/17/20	NAS	Analysis of Mundipharma net working capital by commercial region.	0.60
04/17/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma net working capital analysis and key takeaways from week of 4/13.	1.10
04/17/20	NAS	Call G. Koch (AlixPartners), KPMG, and advisors re: current status of tax workstream.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/17/20	NAS	Draft Mundipharma data request related to days of payables outstanding (DPO) and coordinate with other advisors.	1.40
04/17/20	NAS	Review UCC subpoenas for requests applicable to Mundipharma entities.	0.90
04/17/20	NAS	Analysis of key drivers of discrepancy between Mundipharma year-end estimate of results and actual results.	0.50
04/17/20	IA	Update 2020-2022 Purdue LTRP bridge details to tie to accrual amounts submitted to finance in support of 2020 long term plan financials.	0.90
04/17/20	IA	Call with J. Tran (Avrio) re: changes to Avrio business plan related to Senokot Kiwi products.	0.30
04/17/20	IA	Review outline of Avrio board update re: Kiwi product removal from budget.	0.70
04/17/20	GJK	Discussion with N. Simon (AlixPartners) re: Mundipharma net working capital analysis and key takeaways from week of 4/13.	1.10
04/17/20	GJK	Call N. Simon (AlixPartners), KPMG, and advisors re: current status of tax workstream.	0.60
04/17/20	GJK	Call with J. Turner (PJT) re Mundipharma diligence.	0.30
04/17/20	GJK	Review and comment on UCC subpoena.	1.20
04/17/20	GJK	Continue review of Mundipharma FCF component.	2.00
04/17/20	GJK	Review of Mundipharma FCF component review - by regions.	3.00
04/17/20	JD	Review and provide comments on March flash report in new format for 4/30 Board meeting.	2.40
04/17/20	JD	Correspondence with R. Aleali (Purdue) and J. Turner (PJT) re: creditor presentation.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/17/20	JD	Review creditor presentation comments from J. Lowne (Purdue) and provide comments. Correspondence with J. Lowne (Purdue) and J. Turner (PJT) re: same.	1.00
04/18/20	JD	Draft executive summary for the creditor business plan presentation.	1.50
04/18/20	JD	Call with J. Turner (PJT) re: business plan presentation.	0.30
04/18/20	IA	Update Purdue creditor business plan draft presentation to redact slides based on comments from Purdue legal and remove unnecessary details.	1.60
04/18/20	RDS	Review COA for Rhodes Tech.	0.80
04/19/20	RDS	Review correspondence with Rhodes leadership team regarding cost out opportunities.	0.30
04/19/20	IA	Correspondence with AlixPartners team re: latest draft of creditor presentation and updated to business plan.	0.60
04/19/20	IA	Update creditor draft business plan presentation to include comments received from PJT and AlixPartners teams, for distribution to company for comments.	0.90
04/19/20	JD	Review latest version of the creditor presentation. Provide comments re: same.	0.80
04/19/20	JD	Correspondence with J. Turner (PJT) and M. Kesselman (Purdue) re: latest creditor presentation.	0.70
04/19/20	JD	Correspondence with R. Aleali (Purdue) re: creditor presentation.	0.40
04/20/20	JD	Review latest materials re: Rhodes strategic plan.	0.60
04/20/20	JD	Review comments from R. Aleali (Purdue) re: latest creditor presentation.	0.50
04/20/20	JD	Review draft board deck for removal of Senokot Kiwi from the business plan.	1.00
04/20/20	JD	Correspondence with J. Lowne (Purdue) and J. Turner	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(PJT) re: draft creditor presentation and update to the Avrio plan.	
04/20/20	JD	Review latest designation data against last previously disclosed data.	0.30
04/20/20	JD	Review latest weekly sales data for Purdue and Rhodes.	0.40
04/20/20	JD	Review latest draft creditor business plan presentation.	0.50
04/20/20	GJK	Asses Mundipharma diligence balance sheets between key markets.	2.50
04/20/20	GJK	Call with N. Simon (AlixPartners) re: Mundipharma diligence priorities for week of 4/20.	0.50
04/20/20	GJK	Call with N. Simon (AlixPartners) to review free cash flow assumptions and methodology in Mundipharma model.	0.70
04/20/20	GJK	Coordinate and plan for Mundipharma diligence report.	3.00
04/20/20	IA	Review March results draft report and pull slides to be incorporated in updated draft creditor deck.	1.10
04/20/20	IA	Update Avrio PL allocations file for removal of Senokot Kiwi products and adjustments to S&P spend.	1.80
04/20/20	IA	Update creditor draft business plan presentation based on comments received from Purdue management and PJT.	1.90
04/20/20	IA	Follow up on requests for consent to share third party data on creditor presentation and update summary of data to be disclosed for discussion with third party vendor's Counsel.	1.20
04/20/20	IA	Summarize latest set of questions received from UCC on 2020 business plan and status or reports to be discussed with company and PJT.	0.70
04/20/20	NAS	Finalize Mundipharma request for additional information related to working capital and coordinate with other advisors re: diligence materials received.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/20/20	NAS	Call with G. Koch (AlixPartners) re: Mundipharma diligence priorities for week of 4/20.	0.50
04/20/20	NAS	Revise standalone country P&L in Mundipharma business plan model to use March 2020 sales update methodology.	2.70
04/20/20	NAS	Incorporate free cash flow source data and assumptions in Mundipharma business plan model.	0.80
04/20/20	NAS	Call with G. Koch (AlixPartners) to review free cash flow assumptions and methodology in Mundipharma model.	0.70
04/20/20	NAS	Continue to build free cash flow projections in Mundipharma business plan model for management's projections.	1.20
04/20/20	NAS	Build free cash flow projections in Mundipharma business plan model for region, business line, and product line standalone scenarios.	2.80
04/20/20	MH	Call with vendor to review petition status of invoices and explain claims options.	0.70
04/20/20	MH	Create accounts payable release file.	0.70
04/20/20	RDS	Review updated RT partnership process.	0.30
04/20/20	KM	Review RT partnership process.	0.50
04/20/20	KM	Analysis re: CPP.	1.00
04/20/20	KM	API and COA analysis.	1.50
04/20/20	KM	COA analysis and report.	0.30
04/21/20	KM	Rhodes turnaround planning -- CPP + forecasting.	1.60
04/21/20	KM	Meeting with D. Fogel and D. Lundie (both Purdue) re: Project Catalyst.	0.70
04/21/20	KM	Analysis re: Project Catalyst.	1.70
04/21/20	RDS	Assemble work plans for implementation planning for turnaround initiatives at Rhodes.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/21/20	MH	Create accounts payable release file.	0.70
04/21/20	MH	Redesign accounts payable release program to effect transition to another consultant.	0.30
04/21/20	NAS	Prepare for walk-through of Mundipharma FCF model with J. Arsic (PJT).	0.90
04/21/20	NAS	Draft summary for PJT of underlying methodology for base case and standalone scenarios in Mundipharma business plan/FCF model.	2.00
04/21/20	NAS	Call with J. Arsic (PJT) to review latest draft of Mundipharma FCF model.	0.90
04/21/20	NAS	Respond to follow-up requests and revise Mundipharma FCF assumptions following discussion with J. Arsic (PJT).	1.60
04/21/20	NAS	Discussion with G. Koch (AlixPartners) to provide update on Mundipharma FCF model review with PJT, discuss follow-up requests, and plan diligence priorities.	1.00
04/21/20	IA	Correspondence with PJT re: updated Avrio PL backup files.	0.30
04/21/20	IA	Provide comments to J. Tran (Avrio) re: updated PL allocations file by product.	1.20
04/21/20	IA	Review updated PLs by product for Avrio, compare to prior versions, and summarize adjustments to be incorporated to latest draft of creditor presentation.	2.70
04/21/20	GJK	Review Mundipharma diligence allocations.	2.00
04/21/20	GJK	Discussion with N. Simon (AlixPartners) to provide update on Mundipharma FCF model review with PJT, discuss follow-up requests, and plan diligence priorities.	1.00
04/21/20	GJK	Walkthrough of Mundipharma model process and EBIT comparison.	3.00
04/21/20	GJK	Analysis of NWC comparison between model and the	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/21/20	JD	Arnaud Breabout (Mundipharma) Nov presentation.	
04/21/20	JD	Catch up call with J. Turner (PJT) and R. Aleali (Purdue) re: creditor presentation.	0.50
04/21/20	JD	Review Project Catalyst board update materials.	0.60
04/22/20	JD	Review long term plan model from the Company.	0.70
04/22/20	GJK	Review Mundipharma updated model.	2.50
04/22/20	GJK	Compare Mundipharma 2018 YEE to Actuals.	1.50
04/22/20	GJK	Compare Model FCF vs Evercore FCF.	2.50
04/22/20	GJK	Discussion with N. Simon (AlixPartners) re: Mundipharma diligence priorities for remainder of week.	0.30
04/22/20	GJK	Review and Analysis of Mundipharma current model of product by regions.	2.00
04/22/20	IA	Update Avrio slides in board presentation to exclude Senokot Kiwi products.	2.80
04/22/20	IA	Update expense rationalization slide in board presentation based on latest consolidated numbers.	0.90
04/22/20	IA	Review and response to request from R. Aleali (Purdue) to provide job description for Avrio employee.	0.40
04/22/20	IA	Review updated voluntary separations report received from Purdue HR.	0.40
04/22/20	IA	Call with J. Tran (Avrio) re: PL allocation file and adjustments to innovations.	0.30
04/22/20	IA	Review updated board deck including updated slides from PJT after Avrio adjustments.	1.70
04/22/20	NAS	Draft new Mundipharma diligence request list for Huron following discussion with PJT.	0.60
04/22/20	NAS	Review and revise Mundipharma model methodology document for PJT.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/22/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma diligence priorities for remainder of week.	0.30
04/22/20	NAS	Build net working capital assumption toggle in Mundipharma business plan model and provide latest update to PJT.	1.40
04/22/20	NAS	Finalize standalone country case in Mundipharma business plan model using updated sales methodology.	2.90
04/22/20	NAS	Build check functionality in Mundipharma business plan model for revised individual country case.	1.70
04/22/20	MH	Create accounts payable release file.	0.70
04/22/20	RDS	Call with D. Fogel (Purdue), K. McCafferty (AlixPartners) re: modeling and presentation for strategic partnerships.	1.00
04/22/20	RDS	Update volume / pricing model for strategic partnerships.	1.40
04/22/20	RDS	Create slides re: strategic partnership financial model.	1.10
04/22/20	KM	Business Development: API research.	1.50
04/22/20	KM	Analysis re: Project Catalyst.	1.30
04/22/20	KM	Analysis re: strategic partnership opportunities.	0.50
04/22/20	KM	Call with D. Fogel (Purdue) and R. Sublett (AlixPartners) re: modeling and presentation of strategic partnerships.	1.00
04/23/20	KM	Analysis re: Catalyst partnership opportunities.	0.60
04/23/20	KM	Call with D. Lundie, D. Fogel (both Purdue), R. Sublett (AlixPartners) re: Project Catalyst analysis.	1.10
04/23/20	KM	Analysis re: Project Catalyst financials.	1.00
04/23/20	KM	Call with R. Schnitzler, J. Turner (both PJT), P. Strassburger, D. Lundie, J. Lowne, (all Purdue), R. Sublett (AlixPartners) re: Project Catalyst	0.50
04/23/20	KM	Analysis re: Project Catalyst materials.	0.60
04/23/20	MH	Create accounts payable release file.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/23/20	NAS	Consolidate open items from Mundipharma business plan model prior to discussion with G. Koch (AlixPartners).	0.90
04/23/20	NAS	Call with G. Koch (AlixPartners) to conduct full review of Mundipharma business plan model, determine next revisions, and discuss key takeaways.	2.50
04/23/20	NAS	Revise Mundipharma business plan model (including price/volume build and COGS/unit) following discussion with G. Koch (AlixPartners).	2.60
04/23/20	NAS	Call with G. Koch (AlixPartners) re: revised price/volume build in Mundipharma business plan model.	0.40
04/23/20	NAS	Build high-level Mundipharma COGS per unit analysis at market-by-market level.	0.70
04/23/20	IA	Meeting with E. Nowakowski (Purdue) and I. Arana, S. Lemack (both AlixPartners) to review the 2020 Purdue P&L and Balance Sheet.	1.00
04/23/20	GJK	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue), K. McCafferty, J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case progress and go forward planning.	0.70
04/23/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence.	0.30
04/23/20	GJK	Call with N. Simon (AlixPartners) to conduct full review of Mundipharma business plan model, determine next revisions, and discuss key takeaways.	2.50
04/23/20	GJK	Call with N. Simon (AlixPartners) re: revised price/volume build in Mundipharma business plan model.	0.40
04/23/20	GJK	Review price and cost drivers for adjusted analysis in Purdue model.	2.00
04/23/20	GJK	Follow up with Mundipharma and other advisors on	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		working capital.	
04/23/20	JD	Review side by side analysis prior to mediation meeting.	0.80
04/23/20	JD	Correspondence with R. Aleali (Purdue) re: PwC.	0.20
04/24/20	JD	Call with J. Turner, T. Melvin (both PJT), J. DelConte, A. DePalma (both AlixPartners) re: open diligence items.	0.60
04/24/20	JD	Review Wilson and Coventry site utilization stats.	0.80
04/24/20	JD	Review draft Mundipharma IAC model.	1.00
04/24/20	JD	Review diligence requests from C. Cabello and M. Atkinson (Province).	0.40
04/24/20	JD	Review correspondence re: Province diligence requests.	0.30
04/24/20	JD	Review and provide comments related to comments from M. Kesselman (Purdue) re: creditor presentation.	0.50
04/24/20	JD	Review Intralinks re: materials provided to date.	0.40
04/24/20	GJK	Review Mundipharma model including by country by product.	2.80
04/24/20	GJK	Analysis of Mundipharma model - sales and promotion.	2.50
04/24/20	GJK	Preparation for AlixPartners call including exchanges with I. McClatchy (Norton Rose).	1.00
04/24/20	GJK	Call with N. Simon (AlixPartners) to review unit COGS analysis, discuss next steps for model, and summarize activities for week in advance of team update call.	0.80
04/24/20	NAS	Build analysis of Mundipharma COGS per unit by market.	2.10
04/24/20	NAS	Review follow-up diligence items provided by Huron/Mundipharma.	0.40
04/24/20	NAS	Call with G. Koch (AlixPartners) to review unit COGS analysis, discuss next steps for model, and summarize activities for week in advance of team update call.	0.80
04/24/20	NAS	Build gross margin by product and market functionality in	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma business plan model.	
04/24/20	MH	Create accounts payable release file.	0.70
04/24/20	KM	Analysis re: continued hydromorphone CPP analysis.	0.70
04/24/20	KM	Meeting with D. Fogel (Purdue) and R. Sublett (AlixPartners) re: Project Catalyst insourcing assumptions.	0.50
04/24/20	KM	Analysis re: hydromorphone CPP analysis and re-bidding needs.	1.50
04/24/20	KM	Slide preparation and updating re: Project Catalyst.	0.40
04/24/20	KM	Analysis re: Project Catalyst insourcing opportunities.	1.40
04/24/20	KM	Call with D. Fogel (Purdue), R. Sublett (AlixPartners) re: API market potential.	2.20
04/24/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty (AlixPartners) re: Project Catalyst insourcing assumptions.	0.50
04/24/20	RDS	Call with D. Fogel (Purdue), K. McCafferty (AlixPartners) re: API market potential.	2.20
04/24/20	ADD	Call with J. Turner, T. Melvin (both PJT), J. DeConte, A. DePalma (both AlixPartners) re: open diligence items.	0.60
04/25/20	RDS	Correspondence with D. Fogel (Purdue) re: CPP process.	0.20
04/25/20	GJK	Set-up Mundipharma Diligence Interim Report.	2.50
04/25/20	GJK	Analysis of Mundipharma product category for interim report.	2.50
04/25/20	JD	Review updated executive summary language in the creditor presentation. Provide comments re: same.	0.40
04/26/20	JD	Final review of draft creditor presentation. Provide comments re: same.	1.30
04/26/20	GJK	Analysis of Mundipharma analgesics by country for	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		interim report.	
04/26/20	GJK	Analysis of Mundipharma base case P&L updates.	2.50
04/27/20	GJK	Call with N. Simon (AlixPartners) re: Mundipharma diligence priorities for week of 4/27.	0.40
04/27/20	GJK	Call with N. Simon (AlixPartners) to review sales, gross margin, and selling & promotion cost assumptions for key Mundipharma product/market pairs.	3.50
04/27/20	GJK	Update call with J. Turner (PJT).	0.40
04/27/20	GJK	Review Mundipharma model, margin by market and product.	2.50
04/27/20	GJK	Conduct planning for Mundipharma interim report including identifying key limitations.	3.00
04/27/20	JD	Call with B. Weingarten (Purdue) re: COVID donations.	0.20
04/27/20	JD	Call with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: non-PEO monthly flash report disclosures.	0.40
04/27/20	JD	Call with J. DelConte, I. Arana (both AlixPartners), R. Aleali, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, F. Bivens (both Davis Polk) and S. Birnbaum (Dechert) re: UCC business plan scenario request.	0.60
04/27/20	JD	Follow up call with B. Weingarten (Purdue) re: COVID donations.	0.30
04/27/20	JD	Call with J. Lowne (Purdue) re: business plan scenarios.	0.50
04/27/20	JD	Correspondence with J. Lowne and S. Robertson (Purdue) re: corporate social responsibility budget and spending year to date.	0.70
04/27/20	JD	Review forecast of restricted cash balances from 2020-2029 and correspondence with J. Lowne and E. Ruiz (both Purdue) re: same.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/27/20	JD	Correspondence with M. Huebner (Davis Polk), B. Weingarten and M. Kesselman (Purdue) re: UCC and AHC questions re: COVID donations.	0.80
04/27/20	JD	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: finance and R&D transformation for Rhodes.	0.30
04/27/20	JD	Review materials and analysis re: COVID donations.	2.00
04/27/20	JD	Review Rhodes depreciation and amortization forecast from 2020-2024 in order to answer questions re: same.	0.60
04/27/20	JD	Review updated February flash report prior to uploading.	0.40
04/27/20	MH	Call with supply chain on vendor invoice re: petition status.	0.50
04/27/20	MH	Review invoice to determine correct petition status.	0.40
04/27/20	MH	Meet with analyst to transition accounts payable process.	0.60
04/27/20	MH	Create accounts payable release file.	0.70
04/27/20	NAS	Build check functionality in Mundipharma business plan model for gross margin and unit COGS analyses.	1.40
04/27/20	NAS	Call with G. Koch (AlixPartners) re: Mundipharma diligence priorities for week of 4/27.	0.40
04/27/20	NAS	Create revised priority list in advance of Mundipharma market/product review with G. Koch (AlixPartners).	0.90
04/27/20	NAS	Call with G. Koch (AlixPartners) to review sales, gross margin, and selling & promotion cost assumptions for key Mundipharma product/market pairs.	3.50
04/27/20	NAS	Build selling & promotion expense benchmarks in Mundipharma business plan model following market/product review with G. Koch (AlixPartners).	1.80
04/27/20	IA	Call with Purdue Human Resources team re: employee roster data request for PHI cash flow analysis.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/27/20	IA	Review final version of business plan presentation shared with the committees.	1.10
04/27/20	IA	Call with J. DelConte, I. Arana (both AlixPartners), R. Aleali, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT), M. Huebner, F. Bivens (both Davis Polk) and S. Birnbaum (Dechert) re: UCC business plan scenario request.	0.60
04/27/20	RDS	Preparation of kick-off materials for finance transformation discussion with Rhodes management.	2.50
04/27/20	RDS	Call with D. Fogel (Purdue), K. McCafferty (AlixPartners) re: finance transformation.	0.80
04/27/20	RDS	Call re: financial transformation work plan with S. Rayburn, K. McCafferty, R. Sublett (all AlixPartners).	0.70
04/27/20	RDS	Review of creditor presentation and edits to presentation of free cash flow for one-time items.	0.40
04/27/20	RDS	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: finance and R&D transformation for Rhodes.	0.30
04/27/20	KM	Prepare next phase planning for Rhodes R&D and Finance initiatives.	0.70
04/27/20	KM	Analysis re: IQVIA API volumes.	1.70
04/27/20	KM	Call with D. Fogel (Purdue), R. Sublett (AlixPartners) re: finance transformation.	0.80
04/27/20	KM	Project Catalyst planning.	0.10
04/27/20	KM	Call with J. DelConte, R. Sublett and K. McCafferty (all AlixPartners) re: finance and R&D transformation for Rhodes.	0.30
04/27/20	KM	Workplan development for Rhodes finance re-engineering.	0.90
04/27/20	KM	Project Catalyst strategic planning analysis.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/27/20	KM	Re-engineering rollout plan development.	1.30
04/27/20	KM	Develop financial re-engineering program materials.	1.00
04/27/20	KM	API insourcing rollout materials.	0.50
04/27/20	KM	Call re: financial transformation work plan with S. Rayburn, K. McCafferty, R. Sublett (all AlixPartners).	0.70
04/28/20	KM	Rhodes Finance re-engineering analysis.	1.00
04/28/20	KM	Workplan development re: re-engineering.	0.50
04/28/20	KM	Call with R. Sublett (AlixPartners), D. Fogel (Purdue) and re: finance re-engineering.	1.60
04/28/20	KM	API insourcing analysis.	2.00
04/28/20	KM	Meeting with J. DelConte (AlixPartners) re: Rhodes finance re-engineering plan.	0.30
04/28/20	KM	API insourcing analysis (continued).	0.70
04/28/20	KM	Meeting with W. DiNicola, D. Fogel (both Purdue) re: Project Catalyst.	0.60
04/28/20	KM	Analysis re: go forward strategic options.	0.30
04/28/20	KM	Call with R. Sublett (AlixPartners) re: Catalyst analysis.	0.20
04/28/20	KM	Analysis and slide creation re: Project Catalyst analysis and synopsis.	1.20
04/28/20	RDS	Call with K. McCafferty (AlixPartners) re: Catalyst analysis.	0.20
04/28/20	RDS	Assemble finance transformation materials for meeting with management.	0.60
04/28/20	RDS	Call with K. McCafferty (AlixPartners), D. Fogel (Purdue) re: finance re-engineering.	1.60
04/28/20	RDS	Analysis of latest Project Catalyst materials.	2.20
04/28/20	IA	Calculate severance for current employee roster and	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		rolled out estimates through 2025 for PHI scenario analysis.	
04/28/20	IA	Calculate retention estimates based on latest retention trackers and rolled that out through 2025 for PHI scenario analysis.	1.70
04/28/20	IA	Review updated employee roster for severance analysis in PHI costs scenarios requested by committees.	1.40
04/28/20	NAS	Discussion with G. Koch (AlixPartners) re: Mundipharma Selling & Promotion expense benchmarks.	1.20
04/28/20	NAS	Add new Selling & Promotion expense benchmarks to Mundipharma business plan model.	2.90
04/28/20	NAS	Review new Mundipharma diligence files provided by Huron.	0.50
04/28/20	NAS	Mundipharma product- and market-level review session with G. Koch (AlixPartners) to assess potential adjustments to management forecast.	2.80
04/28/20	NAS	Analysis of Mundipharma historical reporting segment/classification for Rezafungin.	0.80
04/28/20	MH	Advise on hold codes required for accounts payable in light of new situations.	0.20
04/28/20	MH	Create accounts payable release file.	0.70
04/28/20	JD	Call with R. Aleali (Purdue) re: process update and go forward planning.	0.50
04/28/20	JD	Correspondence with M. Huebner (Davis Polk) re: COVID donations.	0.50
04/28/20	JD	Review materials provided by Purdue management re: scenario analysis.	0.80
04/28/20	JD	Meeting with K. McCafferty (AlixPartners) re: Rhodes finance re-engineering plan.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/28/20	GJK	Discussion with N. Simon (AlixPartners) re: Mundipharma Selling & Promotion expense benchmarks.	1.20
04/28/20	GJK	Mundipharma product- and market-level review session with N. Simon (AlixPartners) to assess potential adjustments to management forecast.	2.80
04/28/20	GJK	Analysis of Mundipharma Rezafungin product.	0.50
04/28/20	GJK	Review of Mundipharma model and identification of further adjustments needed for base case.	2.80
04/28/20	GJK	Draft Mundipharma interim diligence report - slide updates, including CH slide.	2.00
04/29/20	GJK	Call with I. McClatchy (Norton Rose) re: diligence process.	0.70
04/29/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) re: update on IAC diligence.	0.50
04/29/20	GJK	Call with B. Bromberg (FTI) re: reforecasted Mundipharma business plan.	0.30
04/29/20	GJK	Discussion with N. Simon (AlixPartners) re: revised Mundipharma management forecast and implications for business plan model and interim report.	1.10
04/29/20	GJK	Calls with N. Simon (AlixPartners) re: status of Mundipharma diligence and review business plan model after incorporating revised forecast.	0.70
04/29/20	GJK	Walkthrough Mundipharma revised business plan.	2.90
04/29/20	GJK	Mundipharma diligence planning activities including follow up exchanges with Huron re: reforecasted business plan.	2.50
04/29/20	JD	Review responses from management re: open diligence questions.	1.00
04/29/20	JD	Review revised Mundipharma budget file.	1.50
04/29/20	JD	Review and provide comments on analysis for UCC	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business planning scenarios.	
04/29/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) re: update on IAC diligence.	0.50
04/29/20	JD	Review historical liquidation analyses related to wind down assumptions.	2.30
04/29/20	JD	Call with J. DelConte, I. Arana (both AlixPartners), J. Lowne (Purdue), J. Turner and R. Schnitzler (both PJT) re: business planning scenarios.	0.80
04/29/20	NAS	Review revised Mundipharma management forecast.	1.60
04/29/20	NAS	Revise Mundipharma business plan model to incorporate new G&A, other income, expenses and R&D per revised forecast.	1.80
04/29/20	NAS	Discussion with G. Koch (AlixPartners) re: revised Mundipharma management forecast and implications for business plan model and interim report.	1.10
04/29/20	NAS	Change fixed/variable cost formulas in Mundipharma business plan model to incorporate revised management forecast.	1.80
04/29/20	NAS	Call with G. Koch (AlixPartners) re: status of Mundipharma diligence and review business plan model after incorporating revised forecast.	0.70
04/29/20	NAS	Ensure all products in Mundipharma business plan model have associated costs and correct where necessary.	2.90
04/29/20	NAS	Revise Mundipharma business plan model to align with management's product reporting segments.	1.60
04/29/20	IA	Call with J. DelConte, I. Arana (both AlixPartners), J. Lowne (Purdue), J. Turner and R. Schnitzler (both PJT) re: business planning scenarios.	0.80
04/29/20	IA	Update PHI cash flow analysis to include comments from	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		J. Lowne and PJT.	
04/29/20	IA	Update PHI cash flow analysis to separate costs for business development assets.	2.20
04/29/20	IA	Call with E. Liesman (Purdue) re: Adhansia headcount in business plan.	0.30
04/29/20	IA	Follow up with human resources on questions re: current employee roster and headcount allocations for PHI cash flow analysis.	0.90
04/29/20	IA	Review April market consumption and market share data for Avrio products.	1.30
04/29/20	RDS	Call with D. Fogel, W. DiNicola (Purdue), K. McCafferty (AlixPartners) re: financial impact of latest data on Project Catalyst.	1.10
04/29/20	RDS	Call with D. Lundie, D. Fogel, W. DiNicola (Purdue), K. McCafferty (AlixPartners) re: Project Catalyst figures to share with board members.	1.40
04/29/20	RDS	Analysis of various scenarios for Project Catalyst.	0.40
04/29/20	KM	Analysis re: Project Catalyst.	1.00
04/29/20	KM	Meeting with D. Fogel, W. DiNicola (both Purdue) re: Project Catalyst.	1.20
04/29/20	KM	Analysis re: API volume and IQVIA analysis.	0.30
04/29/20	KM	Meeting with R. Shamblen (Purdue) re: Project Catalyst.	1.00
04/29/20	KM	Meeting with D. Fogel, W. DiNicola, D. Lundie (all Purdue) re: Catalyst Board slide.	0.50
04/29/20	KM	Meeting with D. Fogel, W. DiNicola (Purdue), R. Sublett (AlixPartners) re: financial impact of latest data on Project Catalyst.	1.10
04/29/20	KM	Analysis re: go forward strategic options.	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/29/20	KM	Analysis re: API volume and IQVIA analysis (continued).	0.30
04/29/20	KM	Call with D. Lundie, D. Fogel, W. DiNicola (Purdue), R. Sublett (AlixPartners) re: Project Catalyst figures to share with board members.	1.40
04/29/20	KM	Analysis re: go forward strategic options (continued).	0.50
04/30/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
04/30/20	KM	Project Catalyst strategic planning review.	0.40
04/30/20	KM	Finance re-engineering data request.	0.50
04/30/20	KM	Analysis re: Project Catalyst strategic options.	1.00
04/30/20	KM	Analysis re: Project Catalyst strategic options (cont.).	0.50
04/30/20	KM	Analysis and summary re: Project Catalyst financial requirements.	2.00
04/30/20	KM	Finance re-engineering survey.	0.60
04/30/20	RDS	Review of third-Party API insourcing opportunity sizing.	0.70
04/30/20	RDS	Review potential insourcing opportunities.	0.70
04/30/20	IA	Update PHI cash flow scenario and costs analysis to include comments from J. Lowne (Purdue).	1.70
04/30/20	IA	Call with J. Lowne (Purdue) and I. Arana, J. DelConte (both AlixPartners) re: updated PHI cash flow scenarios and cost estimates.	0.30
04/30/20	IA	Update PHI cash flow and costs analysis to show additional years for sale scenarios.	1.90
04/30/20	NAS	Compare current Mundipharma business plan model to latest forecast provided by management.	0.30
04/30/20	NAS	Adjust costs for specific products in Mundipharma business plan model following internal discussions.	0.70
04/30/20	NAS	Call with G. Koch (AlixPartners) re: Mundipharma	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		business plan and model walkthrough to review revised S&P model, comparison to management forecast, and new P&L format.	
04/30/20	NAS	Call with D. Freeman (Mundipharma) and Mundipharma diligence advisors re: IQVIA data provided.	0.50
04/30/20	NAS	Revise P&Ls in Mundipharma business plan model to conform with new structure presented in 4/29 revised forecast.	2.90
04/30/20	NAS	Analysis of variance in financials provided by Mundipharma between 2019 year-end estimate and actual performance.	1.00
04/30/20	NAS	Call with G. Koch (AlixPartners) re: review analysis of Mundipharma 2019 year-end estimate vs. actuals and discuss how to revise business plan model.	0.70
04/30/20	NAS	Provide overview of Mundipharma net working capital assumptions for PJT.	1.20
04/30/20	NAS	Analysis of depreciation and amortization line items incorporated in management's revised forecast and ensure alignment with latest draft of Mundipharma business plan model.	1.80
04/30/20	MH	Walkthrough accounts payable release process with M. Hartley (AlixPartners) and S. Lemack (AlixPartners).	0.70
04/30/20	JD	Review pre-read board materials prior to Board meeting.	1.00
04/30/20	JD	Participate in Purdue Board meeting.	3.50
04/30/20	JD	Call with J. Lowne (Purdue) and I. Arana, J. DelConte (both AlixPartners) re: updated PHI cash flow scenarios and cost estimates.	0.30
04/30/20	JD	Call with J. Turner (PJT) and R. Aleali (Purdue) re: post-Board meeting catch up.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
04/30/20	JD	Update latest professional fee forecast for recently filed fee apps.	0.60
04/30/20	JD	Review and provide comments on latest business scenario analysis.	0.70
04/30/20	JD	Review quarterly financial presentations to be provided to the committee advisors.	0.80
04/30/20	GJK	Calls with N. Simon (AlixPartners) re: review analysis of Mundipharma 2019 year-end estimate vs. actuals and discuss how to revise business plan model.	0.70
04/30/20	GJK	Revisions to Mundipharma business model.	0.30
04/30/20	GJK	Call with N. Simon (AlixPartners) re: Mundipharma business plan and model walkthrough to review revised S&P model, comparison to management forecast, and new P&L format.	2.30
04/30/20	GJK	Call with Mundipharma, Huron, Advisor re: IQvia data provided by Mundipharma.	0.50
04/30/20	GJK	Draft Mundipharma interim diligence report - P&L analysis and edits.	3.00
04/30/20	GJK	Draft Mundipharma interim report - business strategy narrative and supporting analysis.	3.00
Total			867.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	6.90	515.00	3,553.50
Sam K Lemack	0.50	515.00	257.50
Hart Ku	6.30	515.00	3,244.50
Nate A Simon	150.90	515.00	77,713.50
David Samikkannu	0.30	690.00	207.00
Isabel Arana de Uriarte	98.20	690.00	67,758.00
Ryan D Sublett	118.30	735.00	86,950.50
Michael Hartley	25.40	840.00	21,336.00
Gabe J Koch	162.50	840.00	136,500.00
Jesse DelConte	124.00	950.00	117,800.00
Kevin M McCafferty	142.60	950.00	135,470.00
Lisa Donahue	31.90	1,195.00	38,120.50
Total Hours & Fees	867.80		688,911.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
04/08/20	JD	Review and provide comments on an outline from C. Robertson (Davis Polk) re: executory contract assumption decision tree.	0.50
04/17/20	JD	Correspondence with E. Diggs (Davis Polk) re: contract database review.	0.40
04/22/20	JD	Participate in a call with T. Melvin and J. Turner (both PJT), E. Diggs, A. Lele (both Davis Polk), J. DelConte, A. DePalma (both AlixPartners) re: NewCo contract transfers.	0.60
04/22/20	JD	Call with J. Lowne (Purdue) re: creditor presentation.	0.20
04/22/20	ADD	Participate in a call with T. Melvin and J. Turner (both PJT), E. Diggs, A. Lele (both Davis Polk), J. DelConte, A. DePalma (both AlixPartners) re: NewCo contract transfers.	0.60
Total			<u>2.30</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Executory Contracts
Client/Matter # 012589.00108

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	0.60	515.00	309.00
Jesse DelConte	1.70	950.00	1,615.00
Total Hours & Fees	2.30		1,924.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
04/21/20	JD	Review latest claims filed summaries.	0.40
04/28/20	JD	Review summary claims report to be posted to Intralinks.	0.40
Total			0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Jesse DelConte	0.80	950.00	760.00
Total Hours & Fees	0.80		760.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
04/01/20	KG	Update SPOT tracking information with documents received to date.	0.60
04/03/20	KG	Create sixth PDF production of documents.	1.80
04/06/20	PM	Re-enable Relativity user and add to group.	0.20
04/10/20	KG	Update SPOT tracking information with documents received to date.	0.60
04/13/20	KG	Create seventh PDF production of documents. Stage and process data for loading. Export and import data into Relativity. Update/overlay data and index for search/retrieval. Generate TIF images and create batches.	3.20
04/13/20	JKL	Quality assurance of production deliverable to ensure counts are accurate and redactions have been applied.	0.80
04/13/20	HEW	QC and deliver production volume.	0.30
04/13/20	PM	Add internal Relativity user to group.	0.10
04/14/20	JKL	Quality assurance of production deliverable to ensure counts are accurate and redactions have been applied.	0.80
04/14/20	KG	Create eighth PDF production of documents.	2.30
04/15/20	HEW	QC and deliver production volume.	0.30
04/19/20	PM	Install blackout application in Relativity workspace.	0.20
04/21/20	TLJ	Preparation of blackout redaction rules to facilitate automated document redactions. Perform quality control review of blackout results.	0.30
04/21/20	KG	Create ninth PDF production of documents. Create and run Blackout projects in Relativity. Create and run search hits in Relativity. Create search term report for delivery.	2.90
04/21/20	JKL	Quality assurance of production deliverable to ensure counts are accurate and redactions have been applied.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
04/22/20	KG	Delivery of production to A. DePalma (AlixPartners). Create and run search terms in Relativity and create a saved search. Generate search hit report.	0.40
Total			15.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Paraskevas Moisakis	0.50	250.00	125.00
Hannah E Wells	0.60	645.00	387.00
Kristina Galbraith	11.80	645.00	7,611.00
Tracy L Jones	0.30	645.00	193.50
Jay K Lynn	2.50	950.00	2,375.00
Total Hours & Fees	15.70		10,691.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
04/02/20	JD	Review and edit February fee statement.	1.80
04/04/20	KMD	Preparation of professional fees for March 2020.	2.20
04/08/20	JD	Provide final comments to finalize February invoice.	0.30
04/08/20	TB	Preparation of 6th Monthly Fee Statement and Exhibits.	1.70
04/10/20	KAS	Review third monthly fee application.	0.60
04/13/20	TB	Email M. Pera, D. Consla, C. Robertson (all Davis Polk) attaching sixth monthly fee application for filing with the Courts.	0.20
04/17/20	TB	Preparation of professional fees for March 2020.	1.00
04/18/20	AML	Preparation of professional fees for March 2020.	3.00
04/18/20	AML	Continue to prepare professional fees for March 2020.	3.00
04/19/20	TB	Preparation of professional fees and expenses for March 2020.	3.00
04/19/20	TB	Preparation of professional fees and expenses for March 2020 (continued).	3.00
04/20/20	TB	Preparation of professional fee for March 2020.	1.50
04/20/20	TB	Continue preparation of professional fees for March 2020.	4.00
04/20/20	AML	Preparation of professional fees for March 2020.	1.50
04/20/20	ESK	Emails with J. DelConte (AlixPartners) re: coordinating time recording activities for the fee application process.	0.30
04/20/20	KAS	Respond to E. Kardos (AlixPartners) re: availability to attend 4/22/20 hearing.	0.10
04/20/20	KAS	Email B. Stavitski (AlixPartners) for 4/22/20 CourtSolutions arrangements.	0.10
04/22/20	KAS	Internal email to L. Donahue, J. DelConte, E. Kardos, L. Verry, B. Stavitski (all AlixPartners), to summarize outcome of the hearing on AlixPartners 1st Interim Fee	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		Application.	
04/22/20	TB	Preparation of professional fees for March 2020.	1.40
04/23/20	TB	Update fee and expense status chart.	0.20
04/23/20	ESK	Email to D. Consla (Davis Polk) confirming AlixPartners' fee and expenses in the draft proposed omnibus order granting the first interim fee application.	0.20
04/23/20	KAS	Review omnibus order re: 1st interim fee applications.	0.30
Total			29.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Andrea M LeBar	7.50	375.00	2,812.50
Kiera M Davids	2.20	415.00	913.00
Tammy Brewer	16.00	450.00	7,200.00
Kaitlyn A Sundt	1.40	510.00	714.00
Elizabeth S Kardos	0.50	710.00	355.00
Jesse DelConte	2.10	950.00	1,995.00
Total Hours & Fees	29.70		13,989.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
04/22/20	KAS	Attend hearing re: 1st Interim fee application.	2.00
04/22/20	NAS	Attend telephonic hearing (partial).	0.30
04/22/20	JD	Participate in Purdue court hearing.	2.00
Total			4.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Kaitlyn A Sundt	2.00	510.00	1,020.00
Nate A Simon	0.30	515.00	154.50
Jesse DelConte	2.00	950.00	1,900.00
Total Hours & Fees	4.30		3,074.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/01/20	RC	Review available bank records in response to requests made by the UCC's advisors and request additional information from the team.	0.30
04/01/20	RC	Review support documentation related to tax distributions.	0.80
04/01/20	RC	Review documentation related to IAC agreements.	0.50
04/01/20	JDH	Prepare documentation support for distributions.	2.30
04/01/20	JDH	Continue preparation of documentation support for distributions.	3.50
04/01/20	JDH	Review of distribution documentation,.	2.40
04/01/20	RC	Call with R. Collura (AlixPartners) and J. Crockett (Province) re: requests for documentation related to transfers to IACs and related follow-up.	0.60
04/01/20	RC	Review cash transfers of value report and request support documentation from team in response to requests from the UCC's advisors.	0.80
04/01/20	RC	Compile list of outstanding requests made to TXP's Counsel and send email requesting a status update.	0.30
04/01/20	RC	Provide documentation to Purdue and Davis Polk re: UCC's request for information.	0.20
04/01/20	RC	Call with R. Collura (AlixPartners) and C. Oluwole (Davis Polk) re: requests for IAC agreements and status of other diligence requests.	0.20
04/01/20	RC	Review distribution related information in response to follow-up question made by the UCC's advisors.	0.70
04/01/20	FOS	Compose email to M. Clarens (Davis Polk) re: status of draft intercompany and non-cash transfers report.	0.20
04/01/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/01/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.90
04/01/20	MFR	Review of emails from R. Collura, A. DePalma (both AlixPartners), Roxana Aleali (Purdue) and Chautney Oluwole (Davis Polk) re: IAC information requests re: licensing agreements. Provided responding email.	0.80
04/02/20	MFR	Call with R. Collura, M. Rule, A. DePalma (all AlixPartners), J. McClammy, C. Oluwole (both Davis Polk), R. Aleali (Purdue), J. Dougherty, and B. Murphy (both Haug Partners) re: status of requests related to IAC agreements and tax information.	0.30
04/02/20	MFR	Review of assumption & assignment agreements from 2017 related to OxyContin license agreements.	0.60
04/02/20	MH	Call with human resources to review options to gather historical payroll tax records.	0.70
04/02/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report (continued).	2.60
04/02/20	JDH	Review of 2016 distribution documentation.	3.50
04/02/20	JDH	Review of 2017 distribution documentation.	2.10
04/02/20	JDH	Distribution of analytics 2011-2015.	1.30
04/02/20	RC	Call with A. DePalma, R. Collura (both AlixPartners) re: status of TXP diligence requests.	0.60
04/02/20	RC	Call with R. Collura, M. Rule, A. DePalma (all AlixPartners), J. McClammy, C. Oluwole (both Davis Polk), R. Aleali (Purdue), J. Dougherty, and B. Murphy (both Haug Partners) re: status of requests related to IAC agreements and tax information.	0.30
04/02/20	RC	Review bank statements compiled in response to the	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		UCC's requests and communicate with Davis Polk about next steps.	
04/02/20	RC	Review distribution support work and provide direction to team on next steps.	0.90
04/02/20	RC	Review and comment on support documentation compiled in response to the UCC's requests.	0.80
04/02/20	RC	Review information related to tax distribution worksheets and calculations.	1.00
04/02/20	RC	Review and analysis of documentation related to transactions with the IACs.	1.20
04/02/20	RC	Review summary of licensing agreement information in advance of call with Haug Partners.	0.20
04/02/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: status of TXP diligence requests.	0.60
04/02/20	ADD	Call with R. Collura, M. Rule, A. DePalma (all AlixPartners), J. McClammy, C. Oluwole (both Davis Polk), R. Aleali (Purdue), J. Dougherty, and B. Murphy (both Haug Partners) re: status of requests related to IAC agreements and tax information.	0.30
04/03/20	RC	Review support documentation related to intercompany transactions.	1.80
04/03/20	RC	Respond to questions from Davis Polk re: requests for organizational charts.	0.20
04/03/20	RC	Review diligence requests from UCC's advisors and information gathered in response to tax requests.	0.80
04/03/20	RC	Review SAP information compiled in response to requests made by the UCC's advisors.	1.10
04/03/20	RC	Review summary of IAC agreement information.	0.30
04/03/20	RC	Review and comment on TXP information request tracker.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/03/20	RC	Review supporting documentation compiled for the intercompany and non-cash transfer of value report.	1.00
04/03/20	RC	Respond to questions from Davis Polk re: bank information requests.	0.30
04/03/20	JDH	Distribution of PPLP 2016 documentation.	3.10
04/03/20	JDH	Distribution of PPLP 2016 documentation.	2.70
04/03/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report.	3.00
04/03/20	MH	Extract data required for historical analysis of payroll withholding amounts.	1.80
04/03/20	MH	Verify historical cash funding process for payrolls in support of historical analysis of withholding amounts.	0.60
04/03/20	FOS	Reconcile SAP data re: accounts receivable data extract to draft intercompany and non-cash transfers report (continued).	1.30
04/03/20	MH	Create analysis of historical payroll withholding amounts for interested parties.	3.30
04/03/20	SJC	Compile distribution support for ex-us distributions.	3.00
04/03/20	SJC	Compile distribution support for ex-us distributions (continued).	2.80
04/03/20	SJC	Compile distribution support for ex-us distributions (continued).	1.00
04/06/20	SJC	Compile distribution support for ex-us distributions (continued).	3.20
04/06/20	MFR	Review of accounts payable analysis.	1.60
04/06/20	MH	Cross reference accounts payable property tax history with general ledger expense entries.	3.70
04/06/20	JDH	Continue to review of 2016 Tax Distributions.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/06/20	JDH	Review of 2016 Tax Distributions.	2.60
04/06/20	JDH	Distribution of PPLP Documentation.	3.40
04/06/20	RC	Additional review and research into support documentation related to Tax Distributions.	1.10
04/06/20	RC	Review intercompany activity and related support documentation.	1.20
04/06/20	RC	Review financial information related to Purdue Pharma Inc.	0.80
04/06/20	RC	Review documentation provided by the family Counsel related to trust structure.	0.70
04/06/20	RC	Review support documentation related to Ex-US distributions.	0.90
04/06/20	RC	Review distribution information in connection with responding to the UCC's information requests.	1.00
04/06/20	RC	Review correspondence with Haug Partners re: requests for tax information.	0.30
04/07/20	RC	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence requests, UCC diligence requests, and open items	0.30
04/07/20	RC	Review and update the TXP and PRA LP information and data request tracker.	0.80
04/07/20	RC	Review and respond to communications with the debtors re: the status of information requests made to TXP and PRA LP.	0.20
04/07/20	RC	Review summary of compensations information related to requests from the UCC.	0.40
04/07/20	RC	Review summary of tax withholding and property tax information related to requests from the UCC.	0.70
04/07/20	RC	Review tracking of IAC agreement related requests.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/07/20	RC	Review status of cash distribution support documentation project.	0.80
04/07/20	JDH	Distribution of 2016 Ex-US documentation.	2.20
04/07/20	JDH	Continue distribution of 2016 Ex-US documentation.	2.20
04/07/20	JDH	Analysis of 2015 Distribution.	2.90
04/07/20	FOS	Call with M. Rule (AlixPartners) re: case status and accounts payable analysis.	0.50
04/07/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.00
04/07/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.40
04/07/20	MFR	Review of accounts payable analysis.	1.40
04/07/20	MFR	Call with F. Silva (AlixPartners) re: case status and accounts payable analysis.	0.50
04/07/20	MFR	Review and reconciliation of licensing agreements received from Norton Rose. Drafted email to R. Collura and A. DePalma (both AlixPartners) re: the UCC's request for licensing agreements.	1.20
04/07/20	SJC	Review support for 2014 distributions.	1.70
04/07/20	SJC	Review support for 2017 distributions.	3.20
04/07/20	SJC	Compile support for 2015 distributions.	3.00
04/07/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence requests, UCC diligence requests, and open items	0.30
04/08/20	SJC	Compile support for 2015 distributions.	3.00
04/08/20	SJC	Compile support for 2015 distributions (continued).	3.10
04/08/20	FOS	Reconcile SAP data re: accounts payable data extract to	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		draft intercompany and non-cash transfers report (continued).	
04/08/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.20
04/08/20	JDH	Distribution of 2014 Tax documentation.	2.80
04/08/20	JDH	Distribution of 2014 Ex US documentation.	2.20
04/08/20	JDH	Continue distribution of 2014 Tax documentation.	2.80
04/08/20	NAS	Respond to follow-up question from R. Collura (AlixPartners) re: Cash Transfers of Value Investigation Report.	0.30
04/08/20	RC	Review agreements compiled in response to the UCC's diligence requests.	0.30
04/08/20	RC	Review organizational charts and respond to questions from Davis Polk.	0.50
04/08/20	RC	Review information and responses to tax information requests.	0.70
04/08/20	RC	Review support documentation related to transactions with IACs.	1.30
04/08/20	RC	Review and respond to team re: requests from UCC's advisors re: diligence requests.	0.10
04/08/20	RC	Review information related to distributions to Purdue Pharma Inc.	0.60
04/08/20	RC	Review IAC information compiled in response to requests from the UCC's advisors.	1.00
04/08/20	RC	Review accounting information related to tax withholding information.	0.40
04/08/20	RC	Review accounting information related to property taxes.	0.30
04/09/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and J. McClammy and C. Oluwole (both Davis Polk) re:	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		bank statement requests and next steps.	
04/09/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: diligence requests and status of responses.	0.60
04/09/20	RC	Review information and respond to requests for historical organizational charts.	0.70
04/09/20	RC	Review information included in the cash transfers of value report in preparation for call with Davis Polk.	0.30
04/09/20	RC	Review bank statement information in response to diligence requests made by the UCC's advisors.	0.80
04/09/20	RC	Review support documentation for cash distributions in response to diligence requests made by the UCC's advisors.	1.10
04/09/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	4.00
04/09/20	SJC	Compile support for 2015 distributions.	2.90
04/09/20	SJC	Compile support for 2015 distributions (continued).	3.00
04/09/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: diligence requests and status of responses.	0.60
04/09/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and J. McClammy and C. Oluwole (both Davis Polk) re: bank statement requests and next steps.	0.30
04/10/20	ADD	Call A. DePalma and R. Collura (AlixPartners) re: UCC follow up diligence requests.	0.30
04/10/20	SJC	Compile support for 2015 distributions.	3.30
04/10/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.20
04/10/20	RC	Call A. DePalma and R. Collura (AlixPartners) re: UCC follow up diligence requests.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/10/20	RC	Review distribution support documentation in response to requests from the UCC.	0.70
04/10/20	RC	Review information related to compensation requests and respond to Davis Polk.	0.50
04/10/20	RC	Review UCC's 2004 requests and subpoena to the Sackler Family members.	0.70
04/11/20	MFR	Review of information and documents related to UCC's request for API sales amounts. Drafted email response to A. DePalma and R. Collura (both AlixPartners) re: the same.	0.60
04/13/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/13/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	3.00
04/13/20	SJC	Compile support for 2015 distributions.	3.00
04/13/20	SJC	Compile support for 2015 distributions (continued).	3.00
04/13/20	SJC	Compile support for 2015 distributions (continued).	2.00
04/13/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) to information requests made by the UCC' advisors.	0.40
04/13/20	RC	Review information available in response to requests made by the UCC's advisors.	1.40
04/13/20	RC	Communicate with the AlixPartners teams re: responding to information requests made by the UCC's advisors.	0.30
04/13/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: responding to requests made by the UCC's advisors.	0.30
04/13/20	RC	Review information gathered in connection with the cash transfers of value report.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/13/20	JDH	Continue documentation of 2014 PPLP distributions.	2.80
04/13/20	JDH	Distribution of documentation of 2014 PPLP.	2.80
04/13/20	JDH	Documentation of 2014 partner distributions.	2.40
04/13/20	JDH	Review of 2014 tax distributions.	1.40
04/13/20	NAS	Respond to questions from R. Collura (AlixPartners) via Counsel re: data sources for Cash Transfers of Value Investigation report.	0.70
04/13/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: responding to requests made by the UCC's advisors.	0.30
04/13/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) to information requests made by the UCC' advisors.	0.40
04/14/20	NAS	Respond to follow-up questions from R. Collura (AlixPartners) via Counsel re: data for Cash Transfers of Value investigation report.	0.60
04/14/20	JDH	Respond to UCC requests.	2.30
04/14/20	JDH	Review of 2014 distribution documentation.	2.30
04/14/20	JDH	Analysis of 2014 Distribution bank statement.	1.40
04/14/20	JDH	Continue review of 2014 distribution documentation.	2.30
04/14/20	RC	Call with R. Collura, M. Hartley and S. Canniff (all AlixPartners) re: review of compensation report obtained.	0.80
04/14/20	RC	Review available compensation information in response to requests from the UCC.	0.60
04/14/20	RC	Preparation of communications to Davis Polk re: UCC's information requests.	0.20
04/14/20	RC	Review information available in response to requests from the UCC.	1.20
04/14/20	SJC	Review of documents received for pension benefits paid	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		to Sackler Family Members.	
04/14/20	SJC	Call with R. Collura, M. Hartley, S. Canniff (all AlixPartners) re: review of compensation report obtained.	0.80
04/14/20	SJC	Review of documents received for expenses paid to Sackler Family Members.	0.40
04/14/20	SJC	Review of documents received for payroll benefits paid to Sackler Family Members.	3.20
04/14/20	SJC	Review of documents received for payroll benefits paid to Sackler Family Members (continued).	3.00
04/14/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.90
04/14/20	FOS	Compose email to M. Rule (AlixPartners) re: Butrans licensing agreements.	0.20
04/14/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.90
04/14/20	MFR	Review of documents for potential information related to Butrans and Mexico. Email response to A. DePalma (AlixPartners) re: the same.	0.60
04/14/20	MFR	Review of emails from A. DePalma (AlixPartners) re: UCC requests about API. Review of information re: to API prior to 2008. Responded via email to A. DePalma (AlixPartners) re: the same.	1.10
04/14/20	MFR	Review of email from F. Silva (AlixPartners) re: Butrans.	0.20
04/14/20	MH	Call with R. Collura, M. Hartley, S. Canniff (all AlixPartners) re: review of compensation report obtained.	0.80
04/14/20	MH	Extract revised accounts payable report for historical payments to equity owners.	0.40
04/14/20	MH	Research data availability for cash transfers prior to 2008.	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/15/20	MFR	Review of historical accounts payable analysis.	2.20
04/15/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/15/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	3.00
04/15/20	SJC	Call with R. Collura, S. Canniff (both AlixPartners) re: responses to UCC's payroll and distribution related requests.	0.80
04/15/20	SJC	Compile support for 2015 distributions.	3.00
04/15/20	SJC	Compile support for 2015 distributions.	3.10
04/15/20	SJC	Review of documents received for payroll benefits paid to Sackler Family Members.	1.10
04/15/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: status of various responses to the UCC's diligence requests.	0.50
04/15/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: TXP request tracker.	0.20
04/15/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's discovery requests and related responses.	0.40
04/15/20	RC	Follow-up call with A. DePalma and R. Collura (both AlixPartners) re: updates to the TXP request tracker.	0.20
04/15/20	RC	Call with R. Collura, S. Canniff (both AlixPartners) re: responses to UCC's payroll and distribution related requests.	0.80
04/15/20	RC	Review summary of payroll information and provide comments.	0.70
04/15/20	RC	Review TXP information request tracker.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/15/20	RC	Review available information in connection with responding to requests from the UCC's advisors.	0.70
04/15/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) re: status of various responses to the UCC's diligence requests.	0.50
04/15/20	ADD	Call with DPW Diligence team re: the status of diligence items.	0.80
04/15/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) re: TXP request tracker.	0.20
04/15/20	ADD	Follow-up call with A. DePalma and R. Collura (both AlixPartners) re: updates to the TXP request tracker.	0.20
04/15/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's discovery requests and related responses.	0.40
04/16/20	ADD	Research Purdue accounting system transaction types.	0.70
04/16/20	RC	Review and update summary of information prepared in response to the UCC's requests.	0.90
04/16/20	RC	Review and comment on updated TXP request tracker.	0.30
04/16/20	RC	Communicate with Davis Polk re: requests for bank statements.	0.10
04/16/20	RC	Review various support documentation gathered in response to requests made by the UCC's advisors.	1.60
04/16/20	RC	Review additional documentation compiled in response to requests related to transactions with IACs.	1.30
04/16/20	RC	Review additional diligence requests and research available information.	0.50
04/16/20	SJC	Review of documents compiled for 2015 distributions.	3.00
04/16/20	SJC	Review of documents compiled for 2015 distributions (continued).	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/16/20	SJC	Compile support for 2013 distributions.	1.30
04/16/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.60
04/16/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.60
04/16/20	FOS	Call with M. Rule (AlixPartners) re: reconciliation of Accounts Payable data to draft intercompany and non-cash transfers report.	0.80
04/16/20	MFR	Call with F. Silva (AlixPartners) re: reconciliation of Accounts Payable data to draft intercompany and non-cash transfers report.	0.80
04/16/20	MFR	Review of accounts payable analysis.	2.10
04/17/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.70
04/17/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.50
04/17/20	SJC	Compile support for 2013 distributions.	3.00
04/17/20	SJC	Compile support for 2013 distributions (continued).	1.70
04/17/20	RC	Review diligence requests from the UCC re: distributions and tax information.	0.20
04/17/20	RC	Review diligence requests from the UCC re: bank statements.	0.10
04/17/20	JDH	Review of 2014 distribution documentation.	2.10
04/17/20	JDH	Continue review of 2014 distribution documentation.	2.40
04/17/20	JDH	Testing of 2012 partner distribution.	1.70
04/19/20	RC	Review correspondence with the UCC's advisors and	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		research status of responding to various requests and identify next steps.	
04/20/20	RC	Review and update information gathered in response to the UCC's requests related to the cash transfers of value report.	1.40
04/20/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: availability of bank statement for the debtor entities.	0.20
04/20/20	RC	Review and respond to questions from Davis Polk re: availability of bank statements for various entities.	0.30
04/20/20	RC	Review summary of distribution selections in connection with gathering information in response to the UCC's requests.	0.80
04/20/20	JDH	Production of 2012 tax distribution document.	2.60
04/20/20	JDH	Production of 2012 non-tax distribution documentation.	3.60
04/20/20	JDH	Continue production of 2012 tax distribution documentation.	2.50
04/20/20	SJC	Compile support for Province selections.	0.50
04/20/20	SJC	Compile support for 2013 distributions.	3.00
04/20/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/20/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	3.00
04/20/20	MFR	Review and edit non-cash transfer report.	3.20
04/20/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: availability of bank statement for the debtor entities.	0.20
04/21/20	MFR	Review and edit non-cash transfer report.	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/21/20	MFR	Call with F. Silva (AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
04/21/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) to review and discuss the intercompany and non-cash transfers of value report.	0.80
04/21/20	FOS	Compose email to K. Shibuya and R. Ellis Ochoa (all AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.20
04/21/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.80
04/21/20	FOS	Call with M. Rule (AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
04/21/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.70
04/21/20	SJC	Compile support for 2013 distributions.	3.00
04/21/20	SJC	Compile support for 2013 distributions.	1.00
04/21/20	SJC	Compile support for 2013 distributions.	3.00
04/21/20	JDH	Distribution of 2012 non-tax documentation.	2.90
04/21/20	JDH	Distribution of 2012 tax documentation.	2.20
04/21/20	JDH	Continue distribution of 2012 non-tax documentation.	2.80
04/21/20	RC	Review information and respond to questions from Davis Polk re: the Special Committee work streams.	0.20
04/21/20	RC	Call with R. Collura, M. Rule (both AlixPartners) to review and discuss the intercompany and non-cash transfers of value report.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/21/20	RC	Review status update for responding to the UCC's distributions requests.	0.20
04/22/20	RC	Review additional information provided by TXP's Counsel and reconciled to specific requests.	1.20
04/22/20	RC	Review supporting documentation related to transactions with the IACs.	1.00
04/22/20	RC	Review documentation related to tax distributions and reconciled to requests made by the UCC.	1.10
04/22/20	RC	Review agreements with IACs collected in response to requests from the UCC.	0.40
04/22/20	RC	Review documentation related transfers to IACs.	0.80
04/22/20	RC	Review documentation gathered in response to the UCC's request for tax-related information.	0.70
04/22/20	RC	Review documentation gathered in response to the UCC's request for bank information.	0.30
04/22/20	JDH	Review of additional bank statements provided by Counsel.	0.90
04/22/20	JDH	Documentation of 2012 tax distribution.	2.40
04/22/20	JDH	Review of 2012 distribution documentation.	3.40
04/22/20	JDH	Continued documentation of 2012 Tax distribution.	2.40
04/22/20	SJC	Compile support for 2015 distributions (continued).	3.00
04/22/20	SJC	Compile support for 2015 distributions.	3.00
04/22/20	FOS	Compose email to K. Shibuya (AlixPartners) re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
04/22/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	3.70
04/22/20	MFR	Review and edit non-cash transfer report.	3.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/23/20	MFR	Review and edit non-cash transfer report.	2.80
04/23/20	MFR	Call with R. Collura, M. Rule and F. Silva (all AlixPartners) and M. Clarens, C. Kim, E. Kim and A. Whisenant (all Davis Polk) re: the intercompany and non-cash transfers of value report and the UCC's diligence requests.	0.60
04/23/20	MFR	Review of outstanding issues tracker. Discussion with F. Silva (AlixPartners) re: the same.	0.60
04/23/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.10
04/23/20	FOS	Call with R. Collura, M. Rule and F. Silva (all AlixPartners) and M. Clarens, C. Kim, E. Kim and A. Whisenant (all Davis Polk) re: the intercompany and non-cash transfers of value report and the UCC's diligence requests.	0.60
04/23/20	FOS	Update Status Tracker re: draft intercompany and non-cash transfers report.	1.20
04/23/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.10
04/23/20	FOS	Review of outstanding issues tracker. Discussion with M. Rule (AlixPartners) re: the same.	0.60
04/23/20	SJC	Compile support for 2015 distributions.	3.00
04/23/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	1.40
04/23/20	JDH	Review of PPLP bank statement production by TXP.	5.70
04/23/20	JDH	Analysis of bank statement production by TXP.	1.60
04/23/20	RC	Call with R. Collura, M. Rule and F. Silva (all AlixPartners) and M. Clarens, C. Kim, E. Kim and A. Whisenant (all Davis Polk) re: the intercompany and non-cash transfers of value report and the UCC's diligence requests.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/23/20	RC	Review license agreements provided by Davis Polk.	0.30
04/23/20	RC	Review and respond to questions from Davis Polk re: TXP's discovery requests.	0.40
04/23/20	RC	Review status update on information provided by TXP and provide team with next steps.	0.30
04/23/20	RC	Review distributions analysis in connection with researching requests made by the UCC's advisors.	1.20
04/23/20	RC	Review status of open items related to the intercompany and non-cash transfers of value report.	0.40
04/23/20	RC	Review TXP request tracker.	0.30
04/23/20	RC	Review additional documents gathered in response to the UCC's requests for IAC related information.	0.80
04/23/20	RC	Review additional documents gathered in response to the UCC's request for tax-related information.	1.00
04/24/20	RC	Review UCC's initial distribution testing selections and related support documentation.	1.80
04/24/20	RC	Review and update latest TXP request tracker and provide to Davis Polk.	0.40
04/24/20	RC	Review analysis and supporting documentation related to transactions with IACs.	0.80
04/24/20	RC	Review updated status of bank statements received from TXP and communicate with the team on next steps.	0.20
04/24/20	RC	Review additional information gathered in response to tax-related requests.	1.10
04/24/20	RC	Research available information in response to the UCC's requests for additional support to cash transfers of value report.	0.70
04/24/20	RC	Update support documentation related to requests for the cash transfers of value report.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/24/20	RC	Review status of outstanding items related to the intercompany analysis.	0.50
04/24/20	JDH	Call with R. Collura, J. Hecht (both AlixPartners) re: distribution support documentation work stream.	0.40
04/24/20	JDH	Analysis of additional bank statements provided by Counsel.	3.60
04/24/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	1.60
04/24/20	JDH	Analysis of 2012 distribution bank statement.	3.20
04/24/20	RC	Call with R. Collura, J. Hecht (both AlixPartners) re: distribution support documentation work stream.	0.40
04/24/20	SJC	Review support for 2015 distributions.	3.00
04/24/20	SJC	Review support for 2015 distributions (continued).	2.80
04/24/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report (continued).	2.30
04/24/20	FOS	Compose email to M. Rule re: reconciliation of SAP accounts payable data extract to draft intercompany and non-cash transfers report.	0.30
04/24/20	FOS	Reconcile SAP data re: accounts payable data extract to draft intercompany and non-cash transfers report.	2.50
04/24/20	FOS	Call with M. Rule (AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.20
04/24/20	MFR	Call with F. Silva (AlixPartners) re: reconciliation of accounts payable data extract to draft intercompany and non-cash transfers report.	0.20
04/24/20	MFR	Review and edit non-cash transfer report.	3.80
04/27/20	MFR	Call with F. Silva (AlixPartners) re: SAP Accounts payable	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		data reconciliation to Draft intercompany and non-cash transfers report.	
04/27/20	MFR	Review of accounting data supporting the non-cash transfer report.	3.00
04/27/20	MFR	Review and edit non-cash transfer report.	2.60
04/27/20	FOS	Compose emails to R. Collura and A. DePalma (both AlixPartners) re: reconciliation of SAP accounts payable data to draft intercompany and non-cash transfers report.	0.20
04/27/20	FOS	Call with M. Rule (AlixPartners) re: SAP Accounts payable data reconciliation to Draft intercompany and non-cash transfers report.	0.20
04/27/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	2.60
04/27/20	FOS	Update draft report re: intercompany and non-cash transfers.	0.50
04/27/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report (continued).	2.50
04/27/20	SJC	Compile support for 2011 distributions.	3.00
04/27/20	SJC	Compile support for 2015 distributions.	3.00
04/27/20	JDH	Prepare bank statement Index.	3.30
04/27/20	JDH	Continue to prepare bank statement index.	1.90
04/27/20	JDH	Continue to prepare bank statement index.	3.20
04/27/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	2.20
04/27/20	RC	Review support documentation for initial set of distribution selections made by the UCC's advisors.	2.20
04/27/20	RC	Review IAC related documentation gathered in response to requests made by the UCC.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/27/20	RC	Review year end files prepared by TXP re: distributions analysis.	2.00
04/27/20	RC	Review documentation related to transactions with IACs and respond to questions from the UCC's advisors.	0.30
04/27/20	RC	Continue to review and comment on documentation related to responses to the UCC's requests.	0.60
04/28/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) re: status of diligence requests and next steps.	0.60
04/28/20	RC	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	1.00
04/28/20	RC	Review summary of additional information provided by TXP in response to requests from the UCC.	0.70
04/28/20	RC	Review and comment on supporting documentation related to tax distribution requests.	1.80
04/28/20	RC	Continue to review supporting documentation compiled in connection with the UCC's tax distribution requests.	1.30
04/28/20	RC	Review and analysis of documentation related to intercompany transactions.	0.80
04/28/20	RC	Review licensing agreements and respond to questions from the UCC's advisors.	0.30
04/28/20	RC	Review documentation related to the debtors' organizational structure and changes over time.	0.20
04/28/20	RC	Review documentation re: transactions with IACs in connection with responding to requests from the UCC.	0.60
04/28/20	JDH	Continue to prepare bank statement index.	2.80
04/28/20	JDH	Continue to review of PPLP bank statement production by TXP.	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/28/20	JDH	Prepare bank statement index.	0.10
04/28/20	JDH	Preliminary draft finalization of the bank statement index.	2.60
04/28/20	SJC	Review of distributions in conjunction with report 1b.	1.00
04/28/20	SJC	Compile support for 2011 distributions.	3.00
04/28/20	SJC	Compile support for 2011 distributions (continued).	3.00
04/28/20	SJC	Compile support for 2011 distributions (continued).	1.00
04/28/20	SJC	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	1.00
04/28/20	FOS	Call with M. Rule (AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
04/28/20	FOS	Review of royalty transfer pricing valuation reports re: ADF Oxycontin, MS Contin between PPLP and IACs.	0.20
04/28/20	FOS	Reconcile SAP accounts payable data re: draft intercompany and non-cash transfers report.	3.90
04/28/20	FOS	Edit draft report re: intercompany and non-cash transfers.	2.50
04/28/20	FOS	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	1.00
04/28/20	MFR	Review and edit non-cash transfer report.	2.80
04/28/20	MFR	Review of accounting data supporting the non-cash transfer report.	2.00
04/28/20	MFR	Call with S. Fernando (AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
04/28/20	MFR	Conference call with R. Collura, M. Rule, F. Silva, S.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	
04/28/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: status of diligence requests and next steps.	0.60
04/28/20	ADD	Conference call with R. Collura, M. Rule, F. Silva, S. Canniff, A. DePalma (all AlixPartners) re: reconciliation of SAP accounts payable data to cash distributions report and draft intercompany and non-cash transfers report.	1.00
04/29/20	MFR	Call with F. Silva (AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
04/29/20	MFR	Conference call with J. Lowne (Purdue), E. Nowakowski (Purdue) and F. Silva (AlixPartners) re: follow-up items on draft intercompany and non-cash transfers report.	1.00
04/29/20	MFR	Review and edit non-cash transfer report.	2.20
04/29/20	MFR	Review of accounting data supporting the non-cash transfer report.	2.10
04/29/20	FOS	Conference call with J. Lowne, E. Nowakowski (all Purdue) and M. Rule (AlixPartners) re: follow-up items on draft intercompany and non-cash transfers report.	1.00
04/29/20	FOS	Edit draft report re: intercompany and non-cash transfers.	0.20
04/29/20	FOS	Compose email to J. Lowne and E. Nowakowski (both Purdue) re: reconciliation of shared services charges between Purdue and Rhodes entities.	0.50
04/29/20	FOS	Compile data re: royalties paid by IACs to Purdue.	2.70
04/29/20	FOS	Call with M. Rule (AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
04/29/20	SJC	Review of distributions in conjunction with report 1b.	3.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/29/20	SJC	Compile support for 2011 distributions.	2.60
04/29/20	SJC	Review support compiled for sample selections for Province and follow up questions.	2.20
04/29/20	JDH	Preliminary draft finalization of the bank statement index.	2.30
04/29/20	JDH	Continue preliminary draft finalization of the bank statement index.	2.30
04/29/20	JDH	Analysis of 2012 distribution bank statement.	2.80
04/29/20	JDH	Review 2012 distribution documentation.	1.40
04/29/20	KS	Perform the QC for Intercompany and Non-Cash Transfers Report.	0.90
04/29/20	RC	Review and analysis of transactions related to intercompany transfer analysis.	1.40
04/29/20	RC	Review and comment of support documentation related to Ex-US Distributions.	1.60
04/29/20	RC	Continue analysis of support documentation related to Ex-US loans and distributions.	1.40
04/29/20	RC	Review and comment on testing analysis for transfers included in the intercompany and non-cash transfer of value report.	0.80
04/29/20	RC	Review documents gathered in response to requests from the UCC related to royalty information.	1.10
04/29/20	REO	Review of support for foreign sales re: foreign sales between 2008-2018 including reconciliation of sales to SAP.	1.50
04/30/20	RC	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence request and status of UCC diligence request.	0.60
04/30/20	RC	Review update re: the UCC's requests for information from the Sackler family.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/30/20	RC	Review documentation related to royalty agreements in connection with responding to the UCC's requests.	0.40
04/30/20	RC	Review support documentation related to intercompany transactions.	0.80
04/30/20	RC	Review and comment on distribution support documentation work stream.	0.30
04/30/20	RC	Review summary of bank statement information.	0.20
04/30/20	RC	Review intercompany transaction documentation and provide comments to team.	0.50
04/30/20	KS	Compile the royalty payments for 2015.	2.50
04/30/20	JDH	Continue review of 2012 distribution documentation	2.70
04/30/20	JDH	Calls and WebEx with J. Koczeniak and W. Sielert (both Mundipharma) to fix SAP access issues.	1.10
04/30/20	JDH	Documentation production of 2010 distribution.	3.10
04/30/20	RC	Review support documentation related to the non-cash transfer analysis.	0.80
04/30/20	RC	Review documentation related to bank statement requests.	0.40
04/30/20	RC	Review tax information documentation gathered in response to the UCC's request.	0.50
04/30/20	SJC	Compile support for 2011 distributions (cont.).	1.10
04/30/20	SJC	Compile support for 2011 distributions.	3.00
04/30/20	SJC	Analysis of 2017 and 2018 royalties for report 1b.	3.00
04/30/20	FOS	Compose email to K. Shibuya, S. Canniff, R. Ellis Ochoa (all AlixPartners) re: compilation of royalty payments from IACs to Purdue.	0.40
04/30/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes (continued).	2.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
04/30/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes.	2.10
04/30/20	MFR	Review of accounting data supporting the non-cash transfer report.	2.70
04/30/20	MFR	Review and edit non-cash transfer report.	2.80
04/30/20	ADD	Call with A. DePalma, R. Collura (both AlixPartners) re: outstanding TXP diligence request and status of UCC diligence request.	0.60
Total			564.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	1.50	420.00	630.00
Andrew D DePalma	8.30	515.00	4,274.50
Nate A Simon	1.60	515.00	824.00
Sam J Canniff	125.10	645.00	80,689.50
Kyoko Shibuya	8.60	645.00	5,547.00
Fernando O Silva	111.30	645.00	71,788.50
Jon D Hecht	140.80	690.00	97,152.00
Michael Hartley	13.40	840.00	11,256.00
Mark F Rule	56.00	910.00	50,960.00
Richard Collura	98.10	1,090.00	106,929.00
Total Hours & Fees	564.70		430,050.50

Exhibit B

Alix Partners, LLP

Summary and Detailed Description of AlixPartners' Expenses

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2
Re: Expense
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
03/02/20	Conference Calls Vendor: Vodafone Ryan Sublett	4.83
03/03/20	Conference Calls Vendor: Vodafone Ryan Sublett	2.35
03/05/20	Conference Calls Vendor: Vodafone Jesse Delconte	13.27
03/06/20	Conference Calls Vendor: Vodafone Ryan Sublett	6.85
03/12/20	Conference Calls Vendor: Vodafone Ryan Sublett	7.48
03/12/20	Conference Calls Vendor: Vodafone Ryan Sublett	0.76
03/12/20	Conference Calls Vendor: Vodafone Ryan Sublett	0.99
03/16/20	Conference Calls Vendor: Vodafone Jesse Delconte	1.56
03/19/20	Conference Calls Vendor: Vodafone Jesse Delconte	26.41
03/25/20	Conference Calls Vendor: Vodafone Ryan Sublett	4.25
03/26/20	Conference Calls Vendor: Vodafone Ryan Sublett	8.46
03/28/20	Conference Calls Vendor: Vodafone Jesse Delconte	18.65
03/31/20	Conference Calls Vendor: Vodafone Ryan Sublett	28.11
04/22/20	Legal Fees Jesse DelConte	70.00
04/22/20	Long Distance Calls Kaitlyn Sundt	70.00
Total Disbursements		263.97

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2124269-2
Re: Expense
Client/Matter # 012589.00150

Disbursement Recap:

Description	Amount
Legal Fees	70.00
Other	193.97
Total Disbursements	<u>263.97</u>